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Neisseria gonorrhoeae, the causative agent of the sexually-transmitted infection
gonorrhea, has recently been labeled a superbug. With dwindling treatment options, there is
urgent need for a gonococcal vaccine. TonB-dependent transporters (TDTs) are important
gonococcal virulence factors that allow the gonococcus to pirate metals directly from host
proteins. The TDTs, TbpA and TbpB, are promising vaccine targets because both proteins are
expressed and highly conserved in gonococcal strains, and they are not subject to highfrequency antigenic variation. Because the Tbps bind to host protein as their natural function,
our immune system does not recognize them as foreign antigens; thus, immunogenicity is
weak. Recent work with Haemophilus parasuis TbpB has demonstrated that pigs vaccinated
with a nonbinding TbpB mutant elicit enhanced immune-cell responses and superior protection
against challenge with H. parasuis compared to pigs vaccinated with WT TbpB.
The extracellular loop 3 helix (L3H) in TbpA is essential for binding to human transferrin
(hTf). Neutral or charge mutations in the L3H are insufficient for abrogating hTf binding;
therefore, this study inserted proline mutations in the L3H to further disrupt the helical
xix

structure and abrogate hTf binding. This study generated several single point mutations in TbpA
that result in significantly decreased hTf binding. Both TbpA D355P and A356P mutants show
significantly reduced hTf-TbpA binding and iron uptake from Fe-loaded hTf. Both TbpA D355P
and A356P vaccine candidates will need to undergo structural studies and testing in a hTf
transgenic mouse model to characterize their true potential as vaccine antigens.
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Chapter 1: Introduction
I.

Neisseriaceae
A. Neisseriaceae
Many changes have affected the classification of the Neisseriaceae family (1). The 1933

classification of Neisseriaceae included four genera: Acinetobacter, Kingella, Moraxella, and
Neisseria (2, 3). Recent rRNA analysis catalyzed reclassification of Moraxella and Acinetobacter
into the new family, Moraxellaceae (2). Eikenella (4), Simonsiella (4), and Alysiella (5) have
been reclassified into the family Neisseriaceae. Neisseriaceae is a family in the class of βproteobacterium and are Gram-negative rods or cocci, often diplococci, are non-motile, and
use aerobic respiration (2, 6). Neisseria produce oxidase, catalase, and often produce acid from
sugars (2, 7).
Neisseria are a part of the normal commensal flora in humans, but a few species are
able to act as opportunistic pathogens (8). Moraxella resides on the mucosa, and under certain
conditions, it can act as an opportunistic pathogen (3). The two neisserial pathogens are
Neisseria meningitidis and Neisseria gonorrhoeae (8). Human commensal and pathogenic
Neisseria spp. can reduce nitrate, produce polysaccharide from sucrose, and produce acid from
carbohydrates (1).
B. Pathogenic Neisseria
i. Neisseria gonorrhoeae
Neisseria gonorrhoeae is the causative agent for gonorrhea, the sexually-transmitted
infection. N. gonorrhoeae is a Gram-negative bacterium, which forms diplococci with flattened
adjacent sides (3). N. gonorrhoeae is an obligate human pathogen with suggestive evidence of
1

gonococcal infection indicated in the bible (Hebrew Bible; Leviticus 15:1–3 (9)). For thousands
of years, N. gonorrhoeae has evolved alongside its only host, and recent evidence suggests
divergence from Neisseria meningitidis (10). This evolution has likely caused pathogenic
Neisseria to be specific to the human host.
ii. Neisseria meningitidis
The main causative agent for bacterial meningitis is Neisseria meningitidis (11-13). Like
the gonococcus, the meningococcus has diplococcal morphology with flattened adjacent sides
(3). Humans are also the only known host for N. meningitidis. Contrary to N. gonorrhoeae,
which is always a pathogen, N. meningitidis can be found residing asymptomatically as an upper
respiratory tract commensal in approximately 1-25% of healthy humans for days to months (6,
12-15). N. meningitidis can produce a capsule that serves many purposes, including aiding in
transmission and colonization and providing protection from desiccation, phagocytosis,
opsonization, and complement fixation (6, 12, 16). Transformation and horizontal gene transfer
allow the meningococcus to switch capsule types as a means of avoiding natural or vaccinespecific protective immunity (6, 17). Meningococcal strains have been grouped into twelve
serogroups based on capsule polysaccharides (3). Five serogroups are most commonly
associated with meningococcal disease: A, B, C, W, Y (12). Categorization of serogroups is
further subdivided into serotypes based on expression of outer membrane proteins, principally
porin (3). Some serotypes are more associated with meningococcal disease than others (3).
Another meningococcal serotyping is based on antigenicity of LOS antigens (3). While the LOS
serotyping is independent of protein serotypes, specific protein and LOS combinations occur
together frequency (3).
2

II.

Meningococcal infection
A. Epidemiology and incidence
N. meningitidis is one of the most common causes of bacterial meningitis, and

meningococcal infection can also cause sepsis and pneumonia (18). Infants, children, and young
adults, especially those living in group settings, are at the highest risk for meningococcal
disease (13). The meningococcus colonizes the human nasopharynx in 5 to 30% of people
without causing disease (3). The highest incidence of invasive meningococcal disease (IMD) is
found in the African meningitis belt, consisting in sub-Saharan countries (18, 19). Other regions
in Africa, Europe, and Australia have more moderate levels of IMD incidence, followed by low
incidence in the Americas and other regions of Europe (18). Serotypes vary by geographical
distribution: serotypes B, C, and Y are more common in the Americans and Europe; whereas,
serogroups A,C,W, and X are more prevalent in Africa (18). Serogroup A causes the highest
incidence of meningococcal disease and has caused repeated pandemics in the African
meningitis belt, as well as Russia and China (6, 20-24). In endemic cases, meningococcal
infection in infants is primarily associated with serogroup B, infection in adolescents is
commonly associated with serogroup C, and serogroups B and Y are more common in older
adults (6, 17, 23, 25-27). Unique to the African meningitis belt, major epidemics of
meningococcal disease occur every few years (6). African epidemics usually start at the onset of
the dry season and end during the rainy season (6). There is evidence suggesting that several
environmental factors such as absolute humidity and dust concentration play roles in the
frequency and size of meningococcal disease epidemics in Africa, but other reasons are poorly
understood (6, 28).
3

B. Disease presentation
Transmission of meningococci occurs via respiratory droplets or throat secretions from
carriers (3, 13). Sexual transmission of N. meningitidis is rare but can occur (6). Inhaled
infectious particles attach to mucosal epithelial cells in the nasopharynx or oropharynx, cross
the mucosal barrier to invade the bloodstream, and if left untreated, can enter the central
nervous system and cause bacterial meningitis (3). Incubation may range between 2 and 10
days; however, death can occur within 24 hours upon dissemination of meningococcal infection
(29).
N. meningitidis survives well in the bloodstream, ultimately causing sepsis or meningitis
(30). Meningococcal infection can manifest in two disease presentations: meningococcemia or
fulminant disease (3). Meningococcemia is characterized by skin lesions and acute bacterial
meningitis (3). Skin lesions are key signs of meningococcemia and can rapidly spread in just a
few hours (3). Fulminant disease has higher mortality and is characterized by multisystem
infection with or without meningitis (3). Symptoms and signs may range in severity, but stiff
neck, high fever, light-sensitivity, headaches, confusion, and vomiting may occur (13). Patients
deficient in complement are at particularly high risk for systemic infections (3, 31, 32).
Meningococcal septicemia is severe, presenting with a hemorrhagic rash and circulatory
collapse (13). Even with rapid treatment, 8-15% of patients will die from meningococcal sepsis
(13). If patients are not treated, only 50% will survive (13). Survivors of meningitis have a 1020% chance of developing brain damage, kidney failure, deafness, and may even require limb
amputation (13, 33).

4

C. Detection and treatment
Detection is accomplished using lumbar puncture to collect purulent spinal fluid (13).
Initial microscopic detection is confirmed by culturing, agglutination tests, or polymerase chain
reaction (PCR) (13). Serotype detection and analysis of antibiotic susceptibility are also
performed (13). Currently the WHO recommends treatment with penicillin, ampicillin, or
ceftriaxone (13). Ceftriaxone is preferred in epidemic regions in Africa due to limited
infrastructure and health resources (13). Treatment should be administered as soon as possible
due to rapid onset of severe meningococcal disease (6). Antibiotics immediately halt
meningococcal proliferation (34, 35), and intravenous administration can kill all meningococci in
cerebrospinal fluid within 3-4 hours (36).
D. Meningococcal vaccines
There are 12 serogroups of N. meningitidis, and 5 are the most common: A, B, C, W, Y
(12). All serogroups except A contain sialic acid derivatives, and the polysaccharide of serogroup
B, alpha (2-8) N-acetyl neuraminic acid (NANA), is identical to human N-CAM (neural cell
adhesion molecule). Not only does serogroup B polysaccharide elicit poor immunogenicity,
there was a concern for safety because the identical polysaccharide poses a risk of crossreactivity to self-antigens (37, 38). Due to these aforementioned concerns, a protein-based
vaccine specific for serogroup B was only just recently developed, despite the high prevalence
of serogroup B disease worldwide (12). Between 2004 and 2008, over one million people were
vaccinated in New Zealand using an outer-membrane vesicle vaccine against N. meningitidis
serogroup B (MeNZB) (39). The Bexsero vaccine, replaced MeNZB, as the first multicomponent
vaccine to provided protection against meningococcal serotype B strains (12). The Bexsero
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vaccine is comprised of four protein antigens: factor H binding protein (FHBP) fused to
GNA2091, neisserial adhesion A (NadA), neisserial heparin-binding antigen (NHBA) fused to
GNA1030, and the MeNZB outer membrane vesicle (OMV) NZ98/254, which contains PorA and
several other antigens (12, 39, 40). Fusion with GNA2091 (41) and GNA030 (42) increase
immunogenicity and serum bactericidal titers. NadA is important for adhesion during
meningococcal colonization, invasion, and pro-inflammatory cytokine induction (12). NHBA is
present in almost all meningococcal strains and inhibits bactericidal activity by binding heparin
(12). In MeNZB, PorA is antigenically diverse and is the main target for bactericidal antibodies
(39, 43). Recent analysis has demonstrated that Bexsero may provide protection against
gonococcal infection (39, 44).
III.

Gonococcal infection
A. Epidemiology and incidence
Reported cases of gonorrhea are much lower than actual cases due to lack of testing

sites and resources, poor reporting, and high prevalence of asymptomatic infections that cause
a patient to not seek out medical treatment (45). The CDC recently released an updated report
suggesting that there were an estimated 1.6 million new cases of gonorrhea per year in the
United States in 2018 (46). The WHO has estimated that there were approximately 87 million
new cases of gonococcal infection worldwide in 2018 (47).
B. Gonorrhea
i. Symptomatic, uncomplicated gonococcal infection
N. gonorrhoeae targets mucosal sites, including the following: urethra, cervix, pharynx,
conjunctiva, and rectum (9). Urogenital infections begin as cervicitis in women or urethritis in
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men (9). Men initially present with urethral purulent exudate, dysuria, and testicular discomfort
(48, 49). In women, the primary site of infection is the endocervical canal, and common
symptoms include vaginal discharge, dysuria, and pelvic pain (9, 50-52). In women, gonococci
can also infect the Bartholin’s glands, situated adjacent to the vaginal introitus, resulting in
pain, edema of the labia, and abscess formation (53). Symptomatic infection is considered
uncomplicated: symptoms direct the patient to seek treatment, but often infections do not
cause symptoms. Gonococcal infection is not protective against reinfection, and may even
increase susceptibility (54).
ii. Asymptomatic, complicated gonococcal infection
Complicated gonococcal infection in men may include orchitis, epididymitis, penile
lymphangitis or edema, and post-infectious urethral strictures (49). Men are more likely than
women to exhibit signs and symptoms of gonococcal infection, resulting in a higher incidence of
severe secondary sequelae in women. An estimated 10- 43% of gonococcal infections in men
are asymptomatic (9, 48); whereas, approximately 50- 80% of cases in women are
asymptomatic (9, 49, 55). If cervicitis is left untreated, the infection can ascend the
reproductive tract and cause severe secondary sequelae such as chronic pelvic pain, pelvic
inflammatory disease, endometritis, infertility, salpingitis, and ectopic pregnancy (45, 56, 57).
iii. Pharyngeal and rectal gonococcal infection
Gonococcal infection of the rectum and pharynx are often asymptomatic; therefore,
infection at these sites are more difficult to detect (49). Rectal gonococcal infections present
with pain, bleeding, discharge, and proctitis (51).
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iv. Conjunctivitis
Gonococcal infection of the eye causes conjunctivitis and can cause blindness if
untreated. Conjunctivitis in adults is primarily caused by autoinoculation. Conjunctivitis is
common in neonates, where the eyes of newborns are infected during birth through passage of
the birth canal. Conjunctivitis is the leading cause of blindness in neonates. If gonorrhea
screening and treatment do not occur during pregnancy, passage through the birth canal
exposes the infant to gonococcal infection, causing conjunctivitis. Conjunctivitis can be treated
with antimicrobial drops; however, as the incidence of antimicrobial resistance increases,
conjunctivitis will be even more difficult to treat.
v. Disseminated gonococcal infection
Disseminated gonococcal infection (DGI) occurs when a localized gonococcal infection
invades the bloodstream. DGI is characterized by skin lesions, polyarthralgia, and tenosynovitis
(58, 59). Only approximately 0.5% to 3% of gonococcal infections disseminate and cause DGI
(60). Clinical manifestations of DGI have been characterized in two stages: the bacteremic stage
and a stage where the infection has been localized to the joint with suppurative arthritis (58).
To survive in the bloodstream, gonococcal strains that cause DGI are serum resistant
(61-63). Complement is known to be important in managing DGI. Approximately 13% of
patients with DGI have deficiencies in complement. Patients deficient in complement have
been found to have a high rate of recurrent bacteremic gonococcal infection (58, 64-66). DGI is
frequently caused by strains with the porin 1A serotype (58, 67). Porin 1A binds to factor H (fH)
and C4b-binding protein (C4BP) to downregulate complement activity (58, 68, 69).
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Women are more susceptible to gonococcal infection during menstruation due to
changes in hormones and an increase in pH (70, 71). Women are even more susceptible to
gonococcal infection during the proliferative stage, due to high estradiol levels, compared to
the luteal stage (72, 73). During menstruation, the phenotypes of gonococci change, causing a
higher risk for dissemination (58). Approximately 50% of women with DGI observe symptoms
within one week of the onset of their menstruation cycle (58). Pregnancy, intrauterine devices,
and history of pelvic surgery can also increase risk of dissemination (60).
Strains auxotrophic for arginine, hypoxanthine, and uracil (Arg-Hyx-Ura-) are highly
resistant to penicillin G and have been associated with asymptomatic gonococcal infection of
the urethra and DGI (74). DGI and asymptomatic urethral infections are less common in men
who have sex with men (MSM) (74). Evidence suggests that auxotrophic strains are less
common in MSM, which may explain the difference in infection phenotype (74). Strains that are
auxotrophic for arginine, hypoxanthine, and uracil appear to be more virulent (61, 75).
Pharyngeal infection may also favor dissemination of gonococci, but the reasons for this is
unknown (61). Recommended treatment of DGI is intravenous administration of 1 g
ceftriaxone, and 1 g oral azithromycin will be added for suspected coinfection with Chlamydia
trachomatis (60). The CDC has recently made the recommendation to discontinue use of
azithromycin for uncomplicated gonococcal infection; however, no recommendations have
been made for DGI (76).
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IV.

Detection, antibiotic resistance, and treatment
A. Detection
Gonococcal infection can be detected in several ways, including direct detection of

gonococci from first-catch urine or swab specimens of urogenital, anorectal, pharyngeal, or
conjunctival mucosal sites (77). Detection can be performed by culturing bacteria from samples,
performing light microscopy of stained smears, or by performing nucleic acid amplification tests
(NAATs). Light microscopy of stained smears can be used to visualize gonococci in urethral or
cervical mucous, but this technique is more specific and sensitive for detection in urethral
discharge (9). Gonococcal detection via NAATs is highly-sensitive: NAATs testing is
approximately 95% sensitive and specific in cervical swabs as well as urethral swabs and firstcatch urine in men (78). As NAATs become more routine, it has shown that rectal and
pharyngeal infections are more common than previously thought (78).
The development of commercially-available point of care assays have allowed for faster
treatment (79). While these commercial assays are convenient and highly-specific, the wide
range of sensitivity leads to a large range of false negative rates, ranging from 13 to 90% (79).
Repeat, follow up screening has shown to be effective in preventing transmission and
eliminating infection (79).
B. Antibiotic resistance and treatment
Treatment guidelines for gonococcal infection have changed often since the 1930’s
(Table 1) (49). Sulfonamides were the first antibiotics used to treat gonococcal infection (45). As
of December 2020, the CDC released new guidelines that recommend discontinuing the use of
dual therapy of 250 mg intramuscular ceftriaxone and 1 g oral azithromycin (76, 80). The new
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recommendation is 500 g intramuscular ceftriaxone in a sole therapy; however, if infection with
C. trachomatis is suspected, 100 mg oral doxycycline is recommended twice a day for 7 days
(76). Patients with cephalosporin or β-lactam allergies can be treated with 1 g intravenous
aztreonam monotherapy. For pharyngeal or rectal gonococcal infections, 2 g of intravenous
aztreonam has shown to be effective (81).
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Effective Years (US)

Table 1. Antimicrobial resistance
Antibiotic
Mechanism
Conferred Resistance

1938-1942

Sulfonamides

Folate synthesis

1944-1987

Β-lactams:
penicilliin

Cell wall synthesis

∼1962-1986

Tetracycline

Inhibits protein synthesis;
targets ribosomal 30S
subunit

∼1967-1986

Doxycycline

∼1962-1986

Spectinomycin

Inhibits protein synthesis;
targets ribosomal 30S
subunit
Inhibits protein synthesis;
targets ribosomal 30S
subunit

∼1990-2007

Quinolones

Inhibits DNA gyrase

Early 1980s-present

Macrolides:
azithromycin
(used in dual
therapy with
ceftriaxone)

Inhibits protein synthesis;
targets ribosomal 50S
subunit

∼1980-present

Thirdgeneration
Cephalosporins

Inhibits cell wall synthesis;
β-lactam
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SNPs in folP that reduce
sulfonamide affinity for DHPS
enzymes
Plasmid-mediated β-lactamase
(TEM-1 and TEM-35); penA
mutations that decrease acylation of
PBP2; ponA mutations that decrease
acylation of PBP1; mrtR promoter
mutations that increase levels of
MtrCDE efflux pump; pilQ mutations
that decrease influx
tetM; ribosome protection; SNPs in
rpsJ; reduction of affinity for 30S
ribosomal subunit protein S10
(V57M)
mtrR; porB1B SNPs

16S rRNA SNP (C1192U) reduces
spectinomycin binding; rpsE
mutations (30S ribosomal protein 5)
disrupt spectinomycin binding
QRDR mutations in gyrA and parC
reduce drug binding to DNA gyrase
and topoisomerase IV, respectively;
overexpression of NorM efflux
pump
23S rRNA SNPs result in a 23S rRNA
target (peptidyltransferase loop of
domain V) with a reduced affinity
for the 50S ribosomal macrolide
target; mtrR promoter mutations
(see above); erm genes (ermB,
ermC,and ermF) encoding rRNA
methylases that methylate
nucleotides in the 23S rRNA target
that block the binding of macrolides;
MacAB efflux pump overexpression
increases the MICs of macrolides;
mef-encoded efflux pump exports
macrolides out of the bacterial cell
and increases the MICs of
macrolides
Non-β-lactamase mechanisms
described; highly remodeled PBP2
due to mosaic penA

V.

Gonococcal vaccine challenges
A. High-frequency antigenic variation
Developing a gonococcal vaccine has proven to be challenging due to the ability of the

gonococcus to undergo high-frequency antigenic or phase variation on surface antigens (45).
High-frequency antigenic variation allows the pathogen to exponentially expand the repertoire
of protein expression on the surface; thus, the host is challenged with producing antibodies to
the vast, changing antigenic surface components (82). There are two types of high-frequency
antigenic variation including RecA-dependent and RecA-independent variation. During DNA
replication, RecA-independent high-frequency phase variation occurs during slipped-strand
mispairing, resulting in a reversible translational frameshift (83).
B. Human gonococcal vaccine trials
There is increasing evidence that the Bexsero vaccine elicits some level of protection against
gonococcal infection. One study characterized antibody production elicited by vaccination of
rabbits with Bexsero antigens that were cross-reactive to N. gonorrhoeae (39). This is further
supported by the sequence conservation between the meningococcal and gonococcal proteins,
except NadA, which is not present in the gonococcus (39). While the gonococcus does not have
a capsule, many of the meningococcal proteins are highly similar to gonococcal proteins.
VI.

Virulence factors
A. Type IV pili
An important virulence factor, located on the gonococci surface, is the type IV pilus

(Figure 1.1) (84). Pili are hair-like structures, approximately 6 nM in diameter, that extend from
the surface of the gonococci and promote adherence to secretory (non-ciliated) epithelial cells
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(85-87). The primary component of the type IV pilus is the polypeptide, pilin (12-22 kDa) (84).
Biogenesis of the pilus is associated with 23 proteins, and begins with assembly, maturation,
counter-retraction, and emergence (88). The main pilin subunit, PilE, assembles to create the
helical structure of the type IV pilus (88, 89). The gene, pilE, is subject to high-frequency
antigenic variation via RecA-dependent recombination, resulting in variations of PilE expression
(90, 91). Nonreciprocal gene conversion occurs between pilE and the silent pilS genes (91, 92).
Function of the type IV pilus is modulated by PilC, PilV, and PilX (90). Gonococcal pilin
expression is subject to phase variation, turning expression on or off (92). Phase variation often
occurs after deletion of pilE1, pilE2 or both pilin genes (92).
Depending on the cell line, pilin may promote or prevent invasion (87, 93). The
gonococcus extends and retracts the pilus to promote invasion of cells (85). Pili bind to host
complement receptors type 3 (CR3) and allows for invasion into cervical epithelial cells by
rearranging host actin to produce membrane ruffling (94-96). Subsequent to membrane ruffling
is the formation of macropinosomes, large vacuoles which contain gonococci (95).
B. Opacity proteins
Opacity proteins (Opa) are outer membrane proteins that are able to promote adhesion,
and in some cases, invasive phenotypes in gonococci (Figure 1.1) (97, 98). Residing in the outer
membrane, the Opa structure consists of eight transmembrane domains and four surfaceexposed loops that contain hyper-variable and semi-variable regions which allow the
gonococcus to change expression of the opas via recombination of Opa proteins intergenically
or between strains (99). The gonococcus encodes approximately 11 Opas; whereas, the
meningococcus encodes 4 to 5 Opas. Opa undergoes phase variation via slipped-strand
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misparing during DNA replication (100, 101). Opa phase variation occurs at the pentameric
pyrimidine tandem repeat sequence, located at the 5’ end of the signal peptide sequence (100,
101). Slipped-strand mispairing allows for varied Opa expression; even in a single colony, each
opa can be turned on or off.
Opa proteins are responsible for essential adhesion, which promotes colonization. Opa
proteins recognize and have specific tropism to human carcinoembryonic antigen cell adhesion
molecules (CEACAMs) or heparin sulphate proteoglycans (HSPG) (99). Different CEACAMs have
select tissue tropism: CEACAM3 is expressed exclusively on neutrophils, and CEACAM1 is
expressed on neutrophils, epithelial cells, and lymphocytes (99). CEACAM3 binding triggers
engulfment of gonococci by neutrophils and subsequent bactericidal killing (99). Opa binding to
CEACAM1 on CD4+ T lymphocyte cells suppresses activation and proliferation (102). Opa binds
to CD66 to facilitate transcytosis of N. gonorrhoeae across polarized epithelial cells (103).
C. Porin
Of the pathogenic Neisseria, the most abundant outer membrane proteins belong to the
class of porins, an important virulence factor (Figure 1.1) (58, 104). Comprised of a trimeric βbarrel structure, porin serves as an aqueous anion channel (104, 105). Meningococcal and
gonococcal porins share approximately 60-70% amino acid similarity with a moderate level of
antigenic variability (106-108). N. meningitidis expresses both PorA (45 kDa) and PorB (33 kDa)
(104, 109); whereas N. gonorrhoeae produces one of two types of PorB: PorB1A (35 kDa) or
PorB1B (37 kDa) (110).
Porin is not only able to interact with eukaryotic cell membranes (111, 112), but it is also
able to insert itself into mammalian cell membranes to create a functional pore, disrupt
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membrane potential, and interfere with cell signaling (104, 113-117). PorB1A of N. gonorrhoeae
is associated with enhanced cell invasion in vitro (111, 118). The role of the meningococcal
porin and invasion of cells has not been as closely evaluated as the gonococcal porins, but there
is evidence that porins may reorganize host actin (119), and they may bind to or insert into the
membrane of host cells (84, 104, 115, 120).
PorB1A allows for DGI by providing higher level serum-resistance to the complement
compared to PorB1B (111). Serum resistance is mediated by PorB1A binding to fH, which
inhibits the alternative complement cascade (69, 104). Several other gonococcal strains
expressing PorB1A can provide serum-resistance to the classical complement pathway by
binding of PorB1A to C4BP (68, 121). PorB in the gonococcus has been shown to induce
apoptosis (104, 122-124); however, meningococcal porins have not been associated with
increased apoptosis (104, 125). Porin is antigenic and has adjuvant-like qualities such as
activation of B cells and other antigen-presenting cells (APC (104)). Porin upregulates CD86
(costimulatory molecule B7-2) in a MyD88-dependent and Toll-like receptor 2-dependent
manner (104). Bactericidal and opsonophagocytic antibodies have been found to target porin
(105).
D. Lipooligosaccharide
N. gonorrhoeae synthesize lipooligosaccharide (LOS). Gonococcal LOS contains three
oligosaccharide chains attached to a lipid A core (126). Lipid A is bound to two heptose residues
via two 2-keto-deoxy-mannoctulosnic acid molecules, and oligosaccharide branches from the
heptose (126). The length of oligosaccharides and number of branches varies among
gonococcal strains (126). The LOS glycosyltransferases (lgtF, lgtE, lgtA, lgtB, lgtD) genes control
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expression of LOS at the surface (126). Of these LOS glycosyltransferase genes, lgtG, lgtA, lgtC,
and ltgD undergo phase variable due to homopolymeric tracts of poly guanine (G) or poly
cytosine (C) tracts (126-128). These homopolymeric tracts cause slipped-strand mispairing
during DNA replication, resulting in premature termination and, ultimately, truncation of LOS
(126, 127). Occurring at a frequency of 10-2 to 10-3 in culture (127), phase variation allows the
gonococcus to change the outer LOS composition to evade an adaptive immune response (126).
The gonococcus can evade all three pathways of complement activity through sialylation
of LOS (Figure 1.1) (126, 129). Sialylation inhibits antibody binding and reduces C1q interaction
to inhibit the classical pathway. Sialylation also inhibits the lectin pathway by reducing mannose
binding lectin (MLB), and fH binding is increased, resulting in significant down-regulation of the
alternate pathway. LOS sialyltransferase (Lst) allows Neisseria to sialylate LOS (130).
Additionally, sialylation reduces complement activation and inhibits C3 fragment deposition to
inhibit opsonization of gonococci. Sialylation is also linked to Opa-mediated invasion in human
epithelial cells. Additionally, LOS binds to sperm cells to promote transmission (131).
E. IgA protease
Neisseria spp. colonizes mucosal sites where IgA is the predominant antibody (132, 133).
IgA is important for its neutralization activity (133). Neisseria spp. release IgA protease as a
virulence factor against IgA antibody activity. IgA protease is classified as an autotransporter
protein, which is a modular protein comprised of the secreted passenger domain, an N-terminal
signal sequence that is exported via the Sec system, and a C-terminal translocator domain (134136).
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Following secretion, the immature form of IgA protease matures after several endoproteolytic cleavages (137). The mature IgA protease then cleaves IgA specifically at the prolinerich hinge region of the IgA1 heavy chain (137, 138). Each Neisseria strain expresses one of two
types of IgA proteases: type 1 protease cleaves at a specific proline/serine bond at position 237,
and type 2 cleaves at a proline/threonine bond at position 235 (139, 140). The proteolytic
activity of IgA protease is unable to cleave IgA2 subclass because it does not have a duplicated
octameric amino acid sequence (137).
IgA protease is also able to cleave lysosome-associated membrane protein 1 (LAMP1),
which is an integral glycoprotein found in late endosomes and lysosomes (139). Cleavage of
LAMP1 results in accelerated degradation, and further promotes survival of intracellular
Neisseria (139, 141).
While anti-IgA protease antibodies can be detected in the cervical mucous of infected
women, the neutralization effect on IgA protease is not significant and thus, not thought to be a
strong defense against gonococcal infection (142, 143). Antibodies to IgA protease are also
detected in sera of both meningococcal infected patients and asymptomatic carriers (140). IgA
protease is not required for gonococcal colonization of the human male urethra, as shown in an
experimental human infection study (132). Evidence suggests that IgA is important for
transcytosis: iga mutants were defective in transcytosis across the epithelium (141).
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Figure 1.1. Gonococcal virulence factors
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Figure 1.1. Gonococcal virulence factors
The gonococcus expresses several important virulence factors. The type IV pilus is important for
initial adherence and colonization. Opa proteins bind to host CEACAMs to promote adherence,
invasion, and transcytosis. The TDTs are important for acquiring essential nutrients, such as
iron. The gonococcus decorates LOS with host sialic acid to evade complement-mediated killing.
Porin promotes cell invasion and inhibits complement deposition and intracellular killing. Image
made with Biorender.com.
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VII.

Animal models
A. Animal model challenges
N. gonorrhoeae is an obligate-human pathogen, meaning that humans are the only

known reservoir for gonococcal infection. Due to this host specificity, evaluating gonococcal
infections in animal models has proven to be challenging. The chimpanzee (Pan troglodytes)
was the first animal model in which it was possible to initiate genital tract infection (144, 145).
Gonococcal urethritis was initiated in three male chimpanzees when human urethral exudates
were transferred to the chimpanzee urethras (144, 145). The genital tract model was further
characterized by presence of N. gonorrhoeae specific complement-fixing antibodies,
transmission among the primates, and purulent conjunctivitis was observed in one chimpanzee,
presumably caused by auto-inoculation (145). Chimpanzees resemble humans anatomically and
physiologically; they share similar blood typing and lysozymes, and chimpanzee IgA can be
cleaved by the gonococcal A protease (138, 144). The limited availability of chimpanzees
suitable for gonococcal infection studies was further reduced as chimpanzees were reallocated
for human immunodeficiency virus (HIV) infection studies in the late 1980s (144). To date, the
only other animal model developed to model genital tract gonococcal infection is performed by
treating female mice with estradiol (146, 147). Estrus is induced and prolonged following
treating with 17β-estradiol; however, antibiotics must be given to reduce the estradiol-induced
overgrowth of commensal bacteria that otherwise prevent gonococcal colonization (148).
Estrus must be induced because female mice are only able to be colonized transiently by
gonococci when mice are in proestrus phase (45). Ovulation in mice initiates robust neutrophil
influx; thus, estradiol is used to suppress cytokine production and change expression of Toll-like
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receptors and effector cells used in protection from infection (45, 149, 150). The estradioltreated mouse model has provided much information to the Neisseria field: including furthering
the understanding of gonococcal colonization and infection, as well as testing vaccination
strategies. Recently, an upper-reproductive tract (URT) mouse model has been developed. N.
gonorrhoeae can be inoculated transcervically directly into the uterine horn of female mice,
either in diestrus-stage or treated with progesterone (151).
B. Transgenic mouse model
N. gonorrhoeae is an obligate human pathogen; therefore, it is no surprise that there
are host restrictions that prevent effective infection of mice (45). Mice lack several receptors
that are key for colonization of gonococci (45). Mice do not express several complement
proteins such as fH and C4BP. While chimpanzees express IgA1, mice do not express IgA1 (45).
Mice also do not have FcαR (CD89), which serves as the opsonophagocytic receptor for IgA (45).
These host restrictions make modeling gonococcal infection difficult, but these results
are also difficult to understand and compare to humans. One of the best ways to make testing
in mice more similar to humans is to utilize transgenic mouse models. Transgenic mouse
models have been made to express the human transgenes such as human CEACAMs (99); CD46
(152); fH (153); C4BP (154); and transferrin (155). Expression of human transgenes in mice
vaccination studies is superior when evaluating host binding proteins, such as TbpA, because
this binding is predicted to interfere with the immune response (156, 157). Binding to host may
prevent activation of the immune response by disguising foreign antigens as host. By
eliminating host binding, antigens are predicted to become exposed and recognized as foreign,
thus, eliciting an immune response.
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VIII.

Innate immune response
A. Cationic antimicrobial peptides
Female genital tract secretions and other mucosa sites contain many antimicrobial

components such as fatty acids, progesterone, and cationic antimicrobial peptides (CAMPs
(45)). CAMPs are bactericidal and modulate the immune system during infection. Epithelial cells
induce expression of CAMPs during infection and phagocytic granules deliver them to the site
of infection (45). The first line of defense against host cytotoxins is the gonococcal MtrCDE
efflux pump (158). In the rectum, bile salts act to inhibit gonococcal colonization (158). The
MtrCDE efflux pump provides enhanced resistance to bile acids, fatty acids, and fecal lipids
isolated from rectal cultures (159, 160). Clinically relevant mtr mutants confer a range of
erythromycin resistance that resembles the same hierarchy of resistance to CAMPS (161). The
gonococcal MtrCDE efflux pump captures LL-37 and removes cathelicidin-related antimicrobial
peptides (161). Additionally, LOS can be modified with phosphoethanolamine (PEA) substitution
on lipid A to inhibit CAMPs from binding to the surface (162).
B. Complement and opsonization
Of the innate immune system, complement is one of the most essential protection
systems against Neisseria infections (62, 129, 154, 163). Complement is very important for
protection against blood infections, and basal levels of complement are naturally high in the
female genital tract (45). In the presence of Neisseria, pattern recognition receptors (PRR)
activate one of two complement systems: the classical pathway or the alternative pathway
(133). The classical pathway functions by insertion of the membrane attack complex (MAC) in
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the bacterial membrane to cause lysis (62, 63). The alternative pathway amplifies complement
component 3 (C3), which allows for opsonization and subsequent intracellular killing (11, 133).
Gonococcal strains range in susceptibility to complement and can be classified as either
serum-sensitive or serum-resistant (164). Serum-sensitive strains are generally more
susceptible to complement; whereas, serum-resistant strains correlate with complement
susceptibility. The ability to resist complement allows for gonococci to invade the blood stream
and cause disseminated gonococcal infection (164). Complement-deficient patients are
significantly more susceptible to invasive meningococcal infection and DGI, and infections are
often recurrent (129, 165, 166). Meningococcal infections are strongly correlated with defects
in the alternative pathway, the most common defect being properdin (Factor D), which
activates the alternative pathway by cleaving factor B (129). Defects of the MAC are associated
almost exclusively with DGI or invasive meningococcal disease (129). Treatment using the
complement inhibitor, Eculizumab, which functions by blocking C5 cleavage, is associated with
high risk of septic Neisseria infections and DGI (129, 167-169). Blocking C5 cleavage prevents
activation of neutrophils and production of the oxidative burst, which is important for bacterial
clearance (129, 170).
N. gonorrhoeae porin binds to C4BP or fH to inhibit activation of the complement (68,
69, 129). Defense against complement is particularly important in preventing dissemination of
both meningococcal and gonococcal infections (31, 58). Complement-dependent killing is also
inhibited by LOS sialylation or PEA substitution of lipid A on LOS (162, 171, 172). Additionally,
LOS sialylation inhibits opsonophagocytosis (173, 174).
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C. Neutrophil killing
Gonococci are resistant to ingestion by polymorphonuclear leukocytes (PMNs) and are
adept at surviving intracellular killing (45). To prevent phagocytosis uptake, gonococci sialylate
LOS, which inhibits C3b deposition (171, 174-176). Phase variation of surface Opa proteins can
generate gonococcal variants that do not bind to neutrophil-specific CEACAMs, allowing the
gonococcus to avoid non-opsonic uptake (177, 178). Additionally, gonococcal isolates
expressing Opa proteins that bind CEACAM1 can downregulate proliferation of CD4+ T-cells and
B-cells to suppress the adaptive immune response (102, 179). Approximately 50% of gonococci
are viable inside PMNs, but the reasons for this are still unclear (45). Gonococci are resistant to
neutrophil oxidative stress defenses (180-182). Gonococci are susceptible to neutrophil killing
despite antioxidant factors including catalase, cytochrome c peroxidase, or quenching via
manganese uptake (183-185). Survival of gonococci in PMNs may depend on suppression of the
phagocytic respiratory burst (180), the delay phagosome fusion with primary granules (186), or
by extracellular release of several peptidoglycans and proteins to promote envelope integrity
and resistance to lysozyme (187, 188).
Because Opa proteins are subject to high-frequency phase and antigenic variation, they
are not ideal vaccine candidates; however, gonococcal Opa binding to CEACAMs is relevant for
discussion in vaccine development (45). The gonococcus binds to CEACAMs depending on
differential Opa expression and promotes bacterial adhesion and tissue invasion (99).
Gonococci expressing Opas that are specific to non-neutrophil CEACAMs allow the gonococcus
to evade phagocytosis; however, human neutrophils constitutively express CEACAM1,
CEACAM3, and CEACAM6 and promote effective phagocytosis of Opa-expressing gonococci (99,
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189). CEACAM3 is expressed exclusively on neutrophils and upon binding, gonococci are
engulfed via non-opsonic phagocytosis and killed via the oxidative burst (99). Because Opa
binding to CEACAM3 does not promote bacterial survival, and there is no known nonbacterial
ligand for CEACAM3, CEACAM3 is speculated to act as a decoy receptor with the goal of
capturing gonococci expressing Opa proteins before they can interact with other cell types
(190). If a vaccine is able to induce antibodies to another surface protein, such as TbpA, antiTbpA antibodies could coat the pathogen and make other receptors on neutrophils, such as
CEACAM3, more available for binding to phagocytes. Additionally, induction of opsonic
antibodies could promote gonococcal opsonization and opsonic phagocytosis, further boosting
intracellular killing of gonococci.
IX.

Iron homeostasis
A. Iron regulation in humans
In humans, iron is stored by various proteins including hemoglobin, ferritin, transferrin,

lactoferrin, and lipocalin (191). Inside erythrocytes, hemoglobin stores approximately 75% of all
the iron in the body, and the remaining 25% is stored by ferritin in liver, spleen, and bone
marrow in hepatocytes and macrophages (192, 193). The hormone hepcidin and its receptor
ferroportin work together to regulate host iron homeostasis. Ferroportin is a receptor on
hepatocytes and macrophages that exports iron into plasma. In iron-replete conditions,
hepcidin binds to and causes endocytosis of the ferroportin receptor to prevent cell iron export
(194). Hepcidin production is induced in infection and inflammation to decrease available
plasma iron (193). Ngo has shown upregulation of hepcidin and downregulation of ferroportin
in infection of monocytes and macrophages, resulting in an increase or iron retention (195).
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Iron retention in macrophages is advantageous to the gonococcus because it inhibits nitric
oxide production, which is important in killing of intracellular bacteria (196). Iron, heme, and
hemoglobin retention in macrophages is also induced during inflammation and tissue damage
(193, 197).
B. Iron sources in humans
i. Transferrin
Only approximately 0.1% of body iron is found extracellularly and is primarily bound by
the glycoprotein transferrin, which acts to chelate and transport iron to cells that require iron
(192). Transferrin is an 80 kDa glycoprotein consisting of an N and C-lobe, wherein each lobe
binds one Fe3+ atom (198, 199). Transferrin is synthesized in the liver, then sent to serum to act
as an iron chelator (198). Serum transferrin is found between 12% and 50% saturation of the
iron-binding capacity, defined as 60 to 75 µM; therefore, serum iron levels range from 10 to 30
µM (191, 200). Transferrin binds with nanomolar affinity (at pH 7.4) to transferrin receptor 1
(TFR1) or transferrin receptor 2 (TFR2) which are expressed on iron-requiring cells (198).
Transferrin binding to TFR triggers clathrin-mediated endocytosis, and endosome acidification
releases Fe3+ into the cytoplasm (201-203).
ii. Lactoferrin
Lactoferrin, or lactotransferrin, is an 80 kDa glycoprotein that has similar structure and
function to the serum glycoprotein transferrin (204-207). Lactoferrin has antimicrobial and antiinflammatory properties (208, 209). Lactoferrin is synthesized by neutrophils and exocrine
glands and is primarily located in human milk and mucosal surfaces (208, 210-216). Lactoferrin
has 60% sequence identity with transferrin and shares a similar structure (217). Apolactoferrin,
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which has no iron bound, has an open conformation; when iron is bound, the N- and C-lobes
close, forming hololactoferrin (218). Like transferrin, lactoferrin binds one ferric iron atom in
each lobe (218-220). Lactoferrin binds with many host receptors: CD14, LDL receptor-related
protein-1, intelectin-1, TLR4, CXCR4, and heparin sulfate proteoglycans (HSPGs (208, 220)).
HSPGs are important for bacterial or viral cell invasion (220-222). Evidence suggests that
lactoferrin-mediated cleavage of Neisseria heparin binding antigen (NHBA) abrogates binding to
HSPGs, thus, inhibiting N. meningitidis adhesion to epithelial cells (223).
Neutrophil extracellular traps (NETs) are formed in a process called NETosis (209).
NETosis occurs by rupture of neutrophil plasma and nuclear membrane, releasing chromatin
fibers and components of neutrophil granules such as lactoferrin, elastase, and
myeloperoxidase (224). NETs trap and kill bacteria as well as modulate acute and chronic
inflammation (208, 209). NET formation is beneficial for host defense in moderation. NET
formation plays a role in massive thrombosis in organs and can trigger or exacerbate
autoimmune disorders (209). Lactoferrin suppresses NETs with its positive charge, and is
hypothesized to be an endogenous NET inhibitor when NETosis levels are too high (209).
Neisseria are able to pirate iron from lactoferrin using LbpA and LbpB (225, 226). Only
50% of gonococcal strains express LbpA; whereas, all meningococcal strains express a
lactoferrin receptor (227, 228). Approximately 30% of lbpA+ gonococcal strains do not express
lbpB, implying that LbpB is not essential for the use of the LbpA receptor (225, 229, 230). In a
male urethra gonococcal infection model, the lactoferrin receptor is able to support
colonization in the absence of the transferrin receptor (225). Together, these findings suggest
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that the lactoferrin receptor is not essential for gonococcal infection but does provide an
advantage (225).
iii. Ferritin
Ferritin is a hollow globular protein, approximately 450 kDa, that acts as the second
largest iron reservoir for the body (231-234). Ferritin stores iron intracellularly in hepatocytes
and hepatic macrophages, and ferritin found in serum is derived from the aforementioned
sources (194). Serum ferritin is relatively iron poor, and low serum ferritin levels roughly
correlate with low iron stored in the body (194, 232). Inflammation, tissue damage, or
hyperferritinemia disease can cause increases in ferritin (194, 235). Ferritin holds iron in the
cytosol to protect cells from the Fenton reactions involved in iron oxidation and mineralization
(236). Iron in ferritin is biologically available and allows for iron to be solubilized (236).
Eukaryotic ferritins are highly conserved, and the structure is characterized with two types of
subunits, H and L, folding in a 4-helical bundle and assembling into a 24-mer shell (232, 236).
Ferritin captures Fe2+ in the ferroxidase center where it is oxidized to Fe3+ using ferroxidase
(236). Iron capture and release from ferritin is still being elucidated (194). During iron-depleted
conditions, ferritin binds to nuclear receptor coactivator 4 to import into the cell in a process
referred to as ferritinophagy (194, 237-240). Ferritin is sent to the autophagy pathway where
ferritin is degraded in lysosomes and iron is released into the cytoplasm (194).
The role of ferritin in Neisseria infection has not been evaluated well. Reduced ferritin
has been shown to inhibit N. meningitidis growth, but no direct interaction has been identified
between the pathogen and ferritin (241). N. meningitidis has also been shown to accelerate
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ferritin degradation to acquire iron in infected host epithelial cells, but the mechanism is not
well understood (242).
iv. Heme/hemoproteins
To maintain proper serum iron levels, hemoglobin is responsible for sequestering free
heme inside erythrocytes (243). Approximately two-thirds of total body iron is stored in heme
groups within hemoglobin, the most abundant protein in blood and erythrocytes (231, 244).
The precursor to hemoglobin is heme, a heterocyclic porphyrin ring that binds centrallycoordinated ferrous iron (Fe2+) (231, 244). Heme can be free or bound to hemoproteins, such as
hemoglobin, haptoglobin, and hemopexin (231). Hemoproteins bind strongly to heme at one or
two of the free iron coordination sites located perpendicularly to the porphyrin ring (231).
Imidazole groups on histidine side chains are the most common ligand for coordination of the
iron in heme, but methionine, cysteine, and tyrosine are also found (231, 245).
Release of heme from hemoglobin may occur spontaneously or by bacterial proteases
(231, 246). Serum proteins, albumin and hemopexin, also rapidly bind and sequester free serum
heme (231). Hemolysis, or spontaneous lysis of erythrocytes, releases hemoglobin into serum,
where tetrameric hemoglobin then dissociates into dimers that are then rapidly sequestered by
haptoglobin (231). Haptoglobin binds hemoglobin almost irreversibly to later be recycled by
macrophages (231, 244, 247). Macrophages have an essential role in recycling iron from
senescent erythrocytes to newly developing erythrocyte precursors (194).
In bacteremic meningococcal infection in the bloodstream, severe disseminated
intravascular coagulation causes erythrocytes to lyse and release hemoglobin in serum (83).
Because of the significant amount of free hemoglobin-haptoglobin (Hb-Hp) complexes in serum
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during meningococcemia, Hb-Hp could be the primary heme source for the meningococcus (83,
248).
Neisseria spp. acquire iron from heme with the two-component TDT system HbuAB,
where HbuB functions as TonB-dependent outer-membrane receptors (249, 250) and HpuA
functions as a lipoprotein (83, 247, 251). HpuAB binds to hemoglobin, Hb-Hp, and apohaptoglobin (83). HpuA and HpuB are required for acquisition of iron in the form of heme from
hemoglobin and Hb-Hp complexes (83, 251-254). The meningococcus expresses a second
hemoglobin receptor, HmbR, which binds to heme (255). Both hpuAB and hmbR undergo phase
variation due to polyguanine (G) tracts (83, 128, 251).
Meningococcal strains express HpuAB or HmbR or both (256); whereas, hmbR is a
frameshifted pseudogene in the gonococcus (257, 258). Dissemination into the blood stream is
less common with the gonococcus; therefore, acquisition of iron from heme is suggested to be
less important than for the meningococcus, which disseminates through the blood stream
during infection (258). However, gonococcal strains isolated from the genital tract of women in
early menses were more likely to express HpuAB, suggesting that the HpuAB expression is
turned phase on by the gonococcus in order to exploit the abundant availability of heme and
hemoglobin (128, 259). Some bacteria can use hemopexin as a source of heme as well as
secrete hemophores that compete with hemopexin (231). It is still unknown if Neisseria are
able to extract heme from albumin or hemopexin.
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X.

Nutritional immunity and iron acquisition
A. Iron and nutritional immunity
Metals such as iron, zinc, and manganese are essential for metabolism in pathogens

(192, 260). Concentrations of metals must be regulated as too much will be toxic to both host
and pathogen and too little will be deleterious to growth and health (192, 260). Iron is most
common metal ion in humans (260, 261). Iron is an essential cofactor for proteins and enzymes
because it readily accepts and donates electrons (261). Oxygen and energy metabolism require
iron to form iron-sulfur (Fe-S) cluster proteins, heme-binding proteins, and RNA reductases
(260, 261). The downstream effects of the aforementioned metabolism allow for heme
synthesis, oxygen transport, and DNA synthesis (193, 260). Iron is also important for immune
cells such as T-lymphocytes and neutrophils (192, 262). An important part of this complex
metal regulation is defined as nutritional immunity. In humans, there are proteins that are used
to sequester metals which prevents a nutrient-replete environment for pathogens to flourish
and prevents metal toxicity (192). Iron is sequestered by transferrin, ferritin, hemoglobin,
haptoglobin, lactoferrin, and lipocalin (191). During inflammation, tissue damage may increase
iron sequestration of iron, heme, and hemoglobin by macrophages (193, 197).
B. Siderophores
Siderophores are low-molecular cages (<1 kDa) that bacteria secrete into the
environment for the purpose of iron acquisition (263-265). Siderophores chelate iron (Fe3+)
with such high specificity and affinity (with a dissociation constant range of 10-22 to 10-52 M),
that iron can be taken directly from host metalloproteins (264, 266). Over five-hundred
siderophores have been described and categorized into three main groups: catecholates,
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hydroxamates, and hydroxycaboxylates (263, 264, 267). In iron-deplete conditions, ironregulated genes are derepressed to initiate siderophore synthesis, which occurs in the
cytoplasm via non-ribosomal peptide synthetases (264, 267). Following synthesis, siderophores
are secreted, scavenge for iron, and transport the iron back to the bacterium (264). Some
bacteria, such as Neisseria, are unable to produce siderophores; however, they are able to use
xenosiderophores, siderophores produced by other bacteria (265, 268, 269). Neisseria can
utilize salmochelin and enterobactin using the outer membrane receptor FetA (266, 268, 270,
271).
To combat the iron-chelation effects of siderophores, the human host uses the protein
siderocalin to sequester siderophores (191, 272). Siderocalin belongs to the lipocalin family of
binding proteins (272). Siderocalin is an important defense mechanism against bacterial
infection: siderocalin knock-out mice are significantly more susceptible to infection compared
to wild-type (WT) mice (273-275). Despite the effectiveness of siderocalins in suppressing
infection, bacteria have evolved strategies to inhibit siderocalin binding to siderophores by
modifying the siderophore with glycosylation or the addition of glucose molecules (276-278).
C. TonB-dependent transporters
A more reliable mechanism for iron acquisition are the TonB-dependent transporters
(TDTs), which are expressed in most Gram-negative bacteria (249, 279). TDTs are highly
conserved in Neisseria and are present in all strains, suggesting that they are important for
survival and virulence (Figure 1.1) (280-285). TDTs are characterized by a beta-barrel structure
residing in the outer membrane, in which a pore allows for import of essential metals such as
iron and zinc into the cytoplasm. Each of these transporters bind to its respective host protein,
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such as transferrin and transferrin-binding protein A (TbpA), lactoferrin and lactoferrin-binding
protein A (LbpA), hemoglobin and hemoglobin-binding protein B (HpuB), calprotectin and TdfH
(286), or S100A7 and TdfJ (287). Under metal duress, pathogens induce expression of these
TDTs to allow for sufficient uptake of these essential nutrients (Figure 1.2) (192).
TDTs use the proton-motive force (PMF) to power the Ton system, which consists of
integral membrane proteins, TonB, ExbB, and ExbD (Figure 1.3) (288). As electrons are
transported during aerobic respiration, a proton gradient is formed across the inner membrane.
This gradient produces the PMF as protons can only cross the cytoplasmic membrane at certain
points, including through ATPase complexes (279). ExbB and ExbD complex act as a motor for
proton translocation (288). This PMF is capitalized upon by TonB as an energy source. PMFderived energy enables TDTs to transport ligand into the periplasm against a concentration
gradient (288). A periplasmic protein then transports the metal ion to an ABC transporter
localized in the inner membrane (279). Any internalized iron is used for essential metabolic
processes to allow for infection and pathogenesis (194, 257).
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Figure 1.2: Host sources of iron
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Figure 1.2: Host sources of iron
The gonococcus expresses outer membrane receptors to directly acquire iron from host
proteins including transferrin (hTf), lactoferrin (Lf), and hemoproteins (Hp). The gonococcus
also expresses a receptor to recognize xenosiderophores, molecular cages produced by other
Gram-negative bacteria. Image made with BioRender.com
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Figure 1.3. The gonococcal outer membrane receptor, TbpA, binds to hTf to hijack and
then internalize iron in a TonB-dependent mechanism.
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Figure 1.3. The gonococcal outer membrane receptor, TbpA, binds to hTf to hijack and
then internalize iron in a TonB-dependent mechanism.
The gonococcal transferrin receptor system includes the outer membrane receptor TbpA and a
lipoprotein TbpB, which facilitates but is not required for iron internalization. Upon hTf binding
to TbpA, a conformational change leads to iron release, resulting in a higher affinity to the plug
domain, located inside the β-barrel of TbpA. TonB, powered by PMF, releases the ligand and
pulls the plug domain into the periplasm. Iron exposure to the periplasm allows for FbpA to
bind to and shuttle the iron ion to an ABC transporter, FbpBC, in the inner membrane, which
internalizes the iron.
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D. Iron regulation in Neisseria
Like the human host, pathogens need to regulate concentrations of metals to find a
complex balance between toxic levels and metal-deplete conditions (289). The Fur regulon
mediates transcription of metal-important genes via the ferric uptake regulator (Fur) protein
(289, 290). Fur has been best characterized in Escherichia coli, but there are known homologs in
other Gram-negative bacteria such as N. gonorrhoeae (291) and N. meningitidis (292, 293). In
high iron concentrations, the Fur protein (15 to 17 kDa) complexes with iron and binds to the
fur box, located upstream of metal-acquisition genes, to prevent unnecessary transcription
(289, 294). In iron-deplete conditions, Fur is derepressed, and RNA polymerase gains access to
the promoter to allow for transcription of iron transport genes, as well as siderophore
biosynthetic enzymes (289, 295). Fur regulation is important in responding to the environment:
if iron is abundant, valuable energy would be lost if these genes were under constitutive
expression (290).
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XI.

Potential vaccine candidates
A. TonB-dependent transporters as vaccine candidates
TDTs are not subject to high-frequency antigenic variation and are highly conserved;

therefore, they have been identified as vaccine candidates for several Gram-negative
pathogens such as Neisseria spp., Haemophilus spp., Moraxella spp., and Actintobacillus spp
(296-303). The gonococcal outer membrane protein, TbpA, and the lipoprotein, TbpB, are
involved in iron acquisition from hTf in a TonB-dependent mechanism (Figure 1.3). A
comparison of TbpA and TbpB can be found in Table 2.
Recombinant TbpA (rTbpA) was first shown to provide protection when used as the sole
immunogen to vaccinate mice against N. meningitidis infection intra-peritoneally, but no
bactericidal activity was observed (304). Rabbits vaccinated with either rTbpA or rTbpB
demonstrate bactericidal activity, with TbpB eliciting the highest levels of bactericidal activity
(304). Intranasal immunization of mice against conjugated TbpA and TbpB to the cholera toxin B
subunit TbpA or TbpB showed similar results: TbpB was more immunogenic, but anti-TbpB
antibodies were less cross-reactive than anti-TbpA antibodies (305). Immunization of mice
using TbpA and TbpB fused to the A2 subunit in cholera and subsequent N. gonorrhoeae
challenge, showed protection against infection; however, TbpB elicited much higher serum IgG
levels compared to TbpA (306). In animals, TbpB has been shown to be more immunogenic
than TbpA, but TbpA is more conserved among Neisseria; therefore, a combination of TbpA and
TbpB is predicted to be more effective than a singular protein vaccine (281, 283, 307).
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Table 2: Comparison of TbpA and TbpB
Characteristics

TbpA

TbpB

Protein type

Outer membrane protein; TonBdependent transporter (308)

Outer membrane lipoprotein (308)

Protein conformation

22-stranded β-barrel (308)

Bilobed with each lobe containing βbarrel domain, side handle domain,
lipid-modified (309, 310)

Size

100-103 kDa (280, 281)

78-85 kDa (281, 309)

Species conservation

Present in all gonococcal isolates to
date (311)

Present in all gonococcal isolates to
date (311)

Susceptible to highfrequency antigenic
variability

No (308)

No (308)

Amino acid sequence
identity scores

95.4-98.1% identity score among
gonococcal isolates and 76.9-96.7%
with meningococcal TbpA (283)

69-84% identity score among
gonococcal isolates and 64-75% with
meningococcal TbpB (281)

Iron repressible

Yes (207)

Yes (308)

hTf binding preference

No hTf binding preference between
saturated or unsaturated hTf (312)

Preferentially binds to saturated hTf
(312, 313)

hTf utilization

Required for hTf utilization (280, 314)

Not required for hTf utilization,
increases efficiency (309, 315)

Growth on hTf plates

TbpA deficient cannot grow on hTf
plates (280, 299)

TbpB deficient can grow on hTf
plates (309)

Immunogenic

Human: no (316)
Mouse: yes (305, 306)

Human: no (316)
Mouse: yes (305, 306)

Binding location on hTf

C-lobe (317)

C-lobe (310)
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B. Nonbinding mutants as vaccine candidates
Humans with natural gonococcal infection do not elicit TbpA or TbpB antibodies in sera
or vaginal secretions, regardless of previous history of gonococcal infection (316). TbpA binds to
hTf, and this binding property is predicted to inhibit the generation of the immune response by
preventing the recognition of the antigen as foreign. To promote antigen recognition as foreign
and development of subsequent protection, the generation of nonbinding mutants has been
proposed and predicted to improve the immune response.
Recent vaccination targets have investigated mutant TDTs that are deficient in binding
to their associated host ligand. TbpA and TbpB in Haemophilus parasuis, the causative agent of
Glässer’s disease in pigs, have been evaluated as vaccine candidates (297, 298, 302, 318, 319).
Vaccination using a WT fragment of rTbpA elicited bactericidal activity (318); however, no
protection could be observed in pigs challenged with H.parasuis (298). Similar vaccine studies
with WT rTbpB from H. parasuis also failed to provide protection (298, 320, 321) despite the
observation of immunogenicity from WT TbpB in N. meningitidis (322) and A.
pleuropneumoniae (323). Follow up studies compared vaccination with either WT TbpB or a
nonbinding TbpB mutant (Y167A) when challenged with H. parasuis (303). The nonbinding
mutant elicited higher cytokine responses and better protection compared to WT TbpB (303). In
fact, pigs vaccinated with the nonbinding mutant demonstrated 100% survival; whereas, pigs
vaccinated with WT TbpB only showed 50% survival (303). A nonbinding mutant of FHBP has
similary been evaluated as a meningococcal vaccine antigen. A nonbinding mutant produced 4to-8-fold higher serum bactericidal antibody responses compared to WT fH in a transgenic
mouse model (156, 303). In human fH transgenic mice, FHBP mutants with reduced binding to
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human complement fH elicited significantly higher IgG titers and serum bactericidal antibody
responses compared to WT FHBP (157). These studies serve as preliminary rationale for
creating a gonococcal vaccine with a nonbinding TbpA mutant that is unable to bind to host
transferrin. The L3H of TbpA is essential for hTf binding and will be targeted for mutagenesis
studies (299, 324). Mutations of the opposite charge or to alanine inserted in the L3H region
were unable to create fully deficient mutants (299). This study is aimed to target mutagenesis
of the L3H region with prolines in an effort to obtain and characterize a nonbinding TbpA
mutant, which can eventually be tested in a transgenic transferrin mouse model.
C. Importance of testing nonbinding TbpA mutants in an hTf transgenic mouse model
TbpA and TbpB generate better immunogenicity in mouse studies, whereas, antibodies
have not been observed in humans (305, 306, 316). One possible explanation for this
observation is the fact that mouse transferrin does not bind to TbpA or TbpB (155, 325), and
this fact is hypothesized to explain why Tbp vaccination studies using WT mice elicit a better
immune response compared to responses elicited in natural infections (305, 306, 316). Because
TbpA and TbpB specifically bind to hTf, the use of hTf transgenic mice will allow for a better
simulation the human response when characterizing the true vaccine potential of a nonbinding
TbpA mutant. Anti-TbpA or anti-TbpB antibodies have not been observed in serum or
secretions in infected humans (316); however, antibodies to both Tbps have been observed in
the serum and vaginal secretions in several WT mouse studies (305, 306). In these studies, antiTbp antibodies demonstrated bactericidal activity and gonococcal growth inhibition (304-306).
The difference in immune response in humans and mice is hypothesized to be a result of the
different Tbp-binding capabilities of mouse and hTf. Mouse transferrin does not bind to TbpA or
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TbpB; therefore, the immune system is able to recognize the Tbps as foreign (325). In the
human, hTf effectively binds to the Tbps and prevents the immune system from recognizing the
antigens as foreign. This study proposes the generation of nonbinding TbpA mutants with
subsequent vaccination testing in the mouse. Because mouse transferrin does not recognize
WT TbpA, it is not expected to recognize a nonbinding mutant; thus, the WT mouse is not a
good model for comparing the two vaccine antigens. To accurately test the true vaccine
potential of a nonbinding TbpA mutant, expression of hTf is the mouse is essential. Following
vaccination with both WT TbpA and the nonbinding mutant, a more accurate comparison of
protection and any elicited immune response will be observed in hTf mice.
Heterozygous hTf transgenic mice were generated in C57BL/6 mice by replacing the
transferrin gene with human transferrin gene using the Cre-Lox recombination system.
Expression of hTf is controlled by the mouse transferrin promotor; thus, hTf expression is
expected to be consistent with natural mouse transferrin expression levels and tissue sites.
Mice with the inverted hTf gene flanked by two loxP (locus of X-over P1) sites were bred with
Cre recombinase mice to generate heterozygous mice expressing both functional transferrin
mouse and hTf (326). (Unpublished).
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Chapter 2: Materials and methods
I. Escherichia coli strains: growth and maintenance
Escherichia coli were routinely cultured in Luria-Bertani broth (10 g tryptone, 10 g NaCl,
5 g yeast extract in 1 L of water (327)) in the presence of the appropriate antibiotic as needed;
ampicillin/carbenicillin (100 µg/mL) or chloramphenicol (34 µg/mL). Plasmids were propagated
in E.coli strains (Table 4): Top10 (Invitrogen), XL-10 Gold (Agilent Technologies), or NEB 5-alpha
(New England BioLabs, NEB). Plasmids were extracted using QIAprep Spin Miniprep Kit
(QIAGEN; 27106) or Zymo Classic Plasmid Miniprep Kit (Zymo Research; D4054). (Table 4)
II. Gonococcal strain growth conditions
Gonococcal cells were propagated using GC medium base (GCB; Difco; Lot 91068340)
with Kellogg’s Supplement I (328) and Supplement II (12 µM Fe(NO3)3) at 35-37°C with 5%
atmospheric CO2. Gonococcal strains were iron-stressed using deferoxamine (desferal; Sigma).
Desferal was reconstituted in sterile MilliQ water at 50 mM and filter sterilized. Gonococcal
strains were iron-stressed by passaging approximately three non-pileated colonies onto 10 µM
desferal GCB agar plates overnight at 36°C with 5% CO2. Cultures were inoculated at 15 to 20
Klett unit (KU) into 5 to 10 mL of liquid Chemically-Defined Medium (CDM, (329)); pretreated
with Chelex 100 (Bio-Rad) in trace-metal free sidearm flasks (Bellco). Cells were grown at 36°C
with 5% CO2 with shaking at 225 RPM until cells doubled to 40 KU. After the doubling event,
cells were typically back diluted to 20 KU and grown an additional 3 to 4 hours.
III. Gonococcal transformation
Two micrograms of plasmid were linearized using SacI (NEB) restriction enzyme in a
total volume of 100 µL. After complete digestion, 10 µL 3M NaOAc (pH 5.2) was added to
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digested plasmid, followed by 250 µL 100% ethanol. Precipitation occurred overnight at -20°C.
Precipitated DNA was centrifuged for 10 minutes at 15,000 RPM, and the pellet was washed
once with 500 µL 70% ethanol. The DNA pellet was allowed to air dry before resuspending into
10 µL of Molecular Biology Grade water. Pileated FA19 was grown overnight on GCB (Difco; Lot:
91068340) plates. Approximately half of a plate was resuspended in 1 mL of alternate GCB
media (40 mL GCB, 400 µL Supp I, 5.2 µL 1M CaCl2 [130 µM final], and 20 µL 1M MgCl2 [50 µM
final]; filter-sterilized with 0.2 µM filter). In a 1.5 mL tube, 10 µL of cell suspension was added to
90 µL alternative GCB media and 5 µL of linearized DNA, as described above. Cells and DNA
were incubated at 36°C with 5% CO2 for 30 minutes. Incubated cells and DNA were then moved
to a 6-well dish with 900 µL of alternative GCB media and incubated at 36°C with 5% CO2. After
approximately 5 hours, 10 to 200 µL of cells were plated onto GCB chloramphenicol plates (1
µg/mL). One hundred microliters of cell suspension were flash frozen and stored at -80°C.
Plates were incubated at 36°C with 5% CO2 for 40-50 hours. Transformed gonococci were flash
frozen and stored at -80°C prior to single colony purification of tbpB-/+.

46

Figure 2.1. Vector map of pUNCH755
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Figure 2.1. Vector map of pUNCH755
Vector, pUNCH755, containing truncated and nonfunctional tbpB upstream of full length tbpA,
a mTn3cat insertion was placed downstream of tbpA. Image created using SnapGene Viewer
5.2.4.
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IV.

Site-directed mutagenesis and generation of gonococcal TbpA mutants
Site-directed mutagenesis utilized pUNCH755 (Figure 2.1) (299, 309)). Primers used for

site-directed mutagenesis and final vector description are located in Table 3 and Table 4. First,
a silent StuI (NEB) restriction site was inserted downstream of the tbpA L3H region in
pUNCH755 by using primers oVCU 905 and oVCU 906, resulting in pGSU001, as described in
Table 3. pGSU001 was used as template for all downstream mutagenesis of tbpA. Because the
silent StuI insertion is unique to pGSU001, tbpA can be amplified from transformed gonococcal
mutants to screen for any WT tbpA, which will not cut with StuI.
Using pGSU001, proline mutations were directed to the L3H region of TbpA between
D355 and Q360 as described in Table 3. Sequences of mutated plasmids were confirmed before
being used for FA19 gonococcal transformation using primers described in Table 5. Following
gonococcal transformation, mutated FA19 strains were purified into tbpA+/tbpB+ and
tbpA+/tbpB- strains using polymerase-chain reaction (PCR). Primers described in Table 5 were
used to amplify tbpA via PCR, and amplicons were digested with StuI to confirm purity of
mutant tbpA. WT tbpA does not contain the StuI site; therefore, only mutant tbpA will cut with
StuI. Single colonies were passaged until no WT tbpA remained. Colonies were also purified into
tbpB+ and tbpB- strains using PCR. The vectors contain truncated tbpB; therefore, both tbpB+
and tbpB- strains will arise from homologous recombination in the gonococcus (Figure 2.2).
These colonies were purified similarly to tbpA. Using PCR and primers described in Table 5,
tbpB was amplified. For both tbpA and tbpB, PCR products were subjected to a 0.7% to 2%
agarose gel in 1X TAE buffer to confirm genotyping. Final gonococcal strains are described in
Table 4.
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Table 3: Mutagenesis primers used in this study. Mutations are identified in bold and underline.
Generated
Plasmid
pGSU001

Generated TbpA Mutation

Target
Plasmid

StuI insert

pUNCH755

D355P

pGSU001

pGSU003

A356P

pGSU001

pGSU004

N357P

pGSU001

pGSU005

Q358P

pGSU001

pGSU006

K359P

pGSU001

pGSU007

K360P

pGSU001

pGSU008

K359P/Q360P

pGSU001

pGSU009

N357P/Q358P/K359P/Q360P

pGSU008

pGSU002

Primer
Name
oVCU 905
oVCU 906
oVCU 927
oVCU 928
oVCU 929
oVCU 930
oVCU 973
oVCU 974
oVCU 975
oVCU 976
oVCU 977
oVCU 978
oVCU 913
oVCU 914
oVCU 917
oVCU 918
oVCU 933
oVCU 934

Direction
Fwd
Rev
Fwd
Rev
Fwd
Rev
Fwd
Rev
Fwd
Rev
Fwd
Rev
Fwd
Rev
Fwd
Rev
Fwd
Rev
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5'-3' Sequence
GGCAACCACAAATACGGAGGCCTGTTTACCAGCGGC
GCCGCTGGTAAACAGGCCTCCGTATTTGTGGTTGCC
AAGGCGGTTTTTCCTGCAAATCAAAAACAGGCG
CGCCTGTTTTTGATTTGCAGGAAAAACCGCCTT
CTGACCAAGGCGGTTTTTGATCCAAATCAAAAACAGGCG
CGCCTGTTTTTGATTTGGATCAAAAACCGCCTTGGTCAG
TTTTGATGCACCTCAAAAACAGGCGGGTTC
ACCGCCTTGGTCAGAAAT
TGATGCAAATCCAAAACAGGCGG
AAAACCGCCTTGGTCAGA
TGCAAATCAACCACAGGCGGGTTC
TCAAAAACCGCCTTGGTC
GATGCAAATCAAAAACCGGCGGGTTCTTTGCGC
CTACGTTTAGTTTTTGGCCGCCCAAGAAACGCG
GATGCAAATCAACCACCGGCGGGTTCTTTGCGC
CTACGTTTAGTTGGTGGCCGCCCAAGAAACGCG
GCGGTTTTTCCTCCACCTCCACCACCGGCGGGTTCTTTGCGC
GCGCAAAGAACCCGCCGGTGGTGGAGGTGGAGGAAAAACCGC

Kit
Agilent
Agilent
Agilent
NEB Q5
NEB Q5
NEB Q5
Agilent
Agilent
Agilent

Table 4: Bacterial strains used in this study
Strain

Description

Source

E. coli
F mcrA (mrr-hsdRMS-mcrBC) 80lacZM15 lacX74 recA1 deoR araD139 (ara-leu)7697 galU
galK rpsL(Strr) endA1 nupG
XL10 Gold
endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte (mcrA)183 (mcrCB-hsdSMR-mrr)173 Tetr F=
UltraCompetent [proAB lacIqZM15 Tn10(Tetr Amyr Cmr)]
NEB 5-alpha
Competent
fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17
Top10

N. gonorrhoeae
FA19
FA6747
FA6815
FA6905
MCV 192
RSC 100
RSC 101
RSC 102
RSC 103
RSC 104
RSC 105
RSC 106
RSC 107
RSC 108
RSC 109
RSC 110
RSC 111
RSC 112
RSC 113
RSC 114
RSC 115

wild-type
TbpA- (tbpA::mTn3cat)
TbpAB- (∆tbpB::Ω)
TbpB- (∆tbpB)
TbpA L3H∆ (T350-A361)
TbpA D355P TbpB- (tbpB∆ T350-A361)
TbpA D355P
TbpA A356P TbpB- (tbpB∆ T350-A361)
TbpA A356P
TbpA N357P TbpB- (tbpB∆ T350-A361)
TbpA N357P
TbpA Q358P TbpB- (tbpB∆ T350-A361)
TbpA Q358P
TbpA K359P TbpB- (tbpB∆ T350-A361)
TbpA K359P
TbpA Q360P TbpB- (tbpB∆ T350-A361)
TbpA Q360P
TbpA K369P + Q360P TbpB- (tbpB∆ T350-A361)
TbpA K369P + Q360P
TbpA N357P + Q358P + K359P+ Q360P TbpB- (tbpB∆ T350-A361)
TbpA N357P + Q358P + K359P + Q360P
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Invitrogen
Agilent Technologies
New England BioLabs

(330)
(280, 312)
(309)
(312)
(299)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Table 5: Amplifying and sequencing primers used in this study
Target

tbpB

tbpA

Primer Name

Use

5'-3' Sequence

oVCU 750

Fwd: tbpB deletion screening

TCGGGCGATGAAGGCGAAACAACTTCCA

oVCU 752

Rev: tbpB deletion screening

CTGCATAAGCGGGCAGCGCAGTCAT

oVCU 993

Rev: tbpB sequencing

GTTCATAACAAACCCGATTC

oVCU 1002

Fwd: tbpB sequencing

CCGGCTGGTTTTACAAACACGC

oVCU 1003

Rev: tbpB sequencing

GCGTGTTTGTAAAACCAGCCGG

oVCU 1004

Rev: tbpB sequencing; starts upstream in tbpA

CGGAACAAATGTTGCTGTTGCAT

oVCU 08

Fwd: tbpA amplification

GACGACGACAAGATGGCGGCATTGGGCGGGACGAGG

oVCU 830J

Rev: tbpA amplification

GACATTGTCCCGGACCGCCGCGTAATAG

oVCU 1005

Fwd: tbpA sequencing

ATGCAACAGCAACATTTGTTCCG

oVCU 1006

Fwd: tbpA sequencing

GAAATCCGCGCCCACGAAG

oVCU 1007

Fwd: tbpA sequencing

CGACCGCGTGATTTACG

oVCU 1008

Fwd: tbpA sequencing

GCCTACCGCGATTTGATTGTCCG

oVCU 1009

Rev: tbpA sequencing

TTAGAACTTCATTTCCAAGCTAAATG
Fwd, Forward; Rev, Reverse
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Figure 2.2. Homologous recombination results in tbpB+ and tbpB- gonococcal strains
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Figure 2.2. Homologous recombination results in tbpB+ and tbpB- gonococcal strains
Description of homologous recombination events using vector pUNCH755 containing truncated
and nonfunctional tbpB upstream of full length tbpA. Crossover events will result in two
genotypes. The top panel shows resulting genotype, tbpA+/tbpB+, when crossover occurs at the
CAT marker and downstream of tbpB. When crossover happens at the CAT marker and
upstream of tbpB, the resulting genotype is tbpA+/tbpB-, as shown in lower panel.
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V. Preparing iron-loaded human transferrin
Human transferrin (hTf; Sigma T2036-500 mg; Lot# SLCC6518) was reconstituted at 10
mg/mL or 125 µM in initial buffer (for 100 mL; 1.214 g Tris [100 mM]; 0.87 g NaCl [150 mM];
0.168 g NaHCO3 [20mM]; pH 8.4; filter-sterilized at 0.2 µM). To achieve 30% Fe-saturation, 75
µL of ferration solution (For 100 mL: 2.94 g Na Citrate [100 mM]; 0.84 g NaHCO3 [100 mM];
0.135 g 5 mM FeCl3 *6 H20; pH 8.4; filter sterilized at 0.2 µM) was added to 10 mL of 125 µM
transferrin + initial buffer and nutated at 4°C for 1 hour. The first dialysis was completed for 4-6
hours at room temperature (RT) using 2 L of dialysis buffer (for 2 L: 9.68 g Tris [40 mM]; 17.4 g
NaCl [150 mM]; 3.36 g NaHCO3 [20 mM]; pH 7.4)/10 mL of transferrin. The second dialysis was
completed overnight at 4°C, followed by filter sterilizing of hTf using 0.2 µM filter. Transferrin is
light-sensitive; thus, it is stored in opaque conical tubes at 4°C.
VI. Protein analysis
A. Whole cell lysates
Whole, iron-stressed gonococcal cell pellets were standardized to 100,000 KU µL and
lysed in 100 µL 2x Laemmli solubilizing buffer (Bio-Rad) supplemented with 5% βMercaptoethanol. Whole cell lysates were boiled at 100°C for 10 minutes.
B. SDS-PAGE
A total of 10-15 µL of lysate was loaded per well onto a 7.5% SDS-PAGE, and gels were
run at 120-150 volts for approximately 1 hour. Proteins were transferred to 0.45 µM
nitrocellulose overnight at 28 milliamps at RT.

55

C. Western blotting
Even protein loading was confirmed via Ponceau S. All blots were blocked for 1 hour at
RT with 5% BSA in high salt-tris buffered saline with 0.05% Tween20 (HS-TBST; 20 mM Tris, 500
mM NaCl [pH 7.5], 0.02% NaN3, 0.05% Tween20). Between antibodies, washes were completed
three times with 1x HS-TBST for 10 minutes. TbpA was probed for by using a 1:5,000 dilution of
polyclonal rabbit serum (11581-B6) against full-length TbpA (280). A 1:3,000 dilution of goat
anti-human transferrin (Sigma #T2027) was used to detect hTf. A 1:15,000 dilution of goat antirabbit IgG conjugated to horseradish peroxidase (HRP; Bio-Rad) or a 1:5,000 dilution of rabbit
anti-goat IgG HRP (Bio-Rad) were used as secondary antibodies for TbpA and hTf, respectively.
OPTI-C4N (Bio-Rad) or West Femto (Thermo) were used as substrates per manufacturers
recommendations. Images were taken using Bio-Rad Chemidoc System.
VII. Protease digestion assay
Protease accessibility assays were completed using trypsin as previously described
(312). FA19 WT and mutant strains were grown as described above to doubling point, backdiluted, and grown for 3-4 hours at 36°C with 5% CO2. Whole, iron-stressed gonococci were
treated with 12.5 µL reconstituted trypsin (Sigma)/5 mL of culture for 0, 10, 20, and 30 minutes
at 36°C with 5% CO2. Reactions were quenched with 75 µL or 0.6 trypsin-inhibiting units of
aprotinin (Sigma). Whole cell lysates were collected and subjected to western blotting for TbpA
as described above.
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VIII. Growth on CDM plates with 30% Fe-saturated human transferrin as the sole source of
iron
CDM agarose plates were made with ultrapure agarose (Invitrogen; catalog# 16500-500;
Lot# 004X5P) that had been prepared in advance. All preparation of ultrapure agarose was
competed in acid-washed glass. First, 500 g agarose was washed twice with 1 L MilliQ water for
1 hour at RT, washed twice with 1 L 100% ethanol at RT, and washed twice with 1 L of methanol
at RT. Centrifugation steps were completed at 3800 x g. After the final wash, agarose was
placed in an aluminum foil-covered casserole dish in the biosafety cabinet and stirred
occasionally to allow for complete evaporation of alcohols. CDM agarose plates were made
using the following recipe for 100 mL: 1 g washed ultrapure agarose, 0.5 g potato starch, and 75
mL VA water were autoclaved. Autoclaved media was allowed to cool before addition of 25 mL
of 4X CDM, 25 µL Solution 6, 107 µL Solution 7, 2 mL Solution 8, and 2 mL of 30% Fe-saturated
hTf. To solidified CDM agarose plates, approximately equivalent amounts of gonococcal strains
were streaked and incubated for 48 hours at 36°C with 5% CO2. Images were taken with BioRad ChemiDoc.
IX. Growth in liquid CDM using 30% Fe-saturated human transferrin as the sole source of
iron
Strains were streaked onto GCB plates supplemented with 10 µM desferal and
incubated at 36°C with 5% CO2 for 12-16 hours. Iron-starved strains were inoculated into liquid
CDM as described above. After doubling, cells were back diluted to 2 × 10 -5 OD600 with 1x CDM,
and 100 µL of dilution was plated per well into 96-well plates, pretreated with 5 µM desferal
and 5 µM hTf. BioTek Synergy and Cytation plate readers were used to incubate the cells at
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36°C with 5% CO2 with continuous orbital shaking (Frequency: 180 cpm (6 mm). The OD600 was
plotted over 24 hours. Statistical analysis was performed using GraphPad Prism 9.0. A two-way
analysis of variance (ANOVA) with Tukey’s post-hoc was performed on 3 technical replicates.
X. Transferrin-binding ELISA
Human transferrin was prepared as previously described above. Strains were ironstarved on GCB plates supplemented with 12.5 µM desferal overnight to induce TbpA
expression. MaxiSorp microtiter plates (Nunc) were treated with 100 µL 0.01% poly-lysine in
H2O (Sigma P8920-100ML; Lot# SLBZ7200) overnight at 4°C. Cultures were standardized to 1.0
OD600 and 100 µL per strain was incubated in sextuplicate wells for 1 hour at RT. Excess cell
suspension was removed and cells were blocked with 200 µL 3% bovine serum albumin (BSA) in
1x PBS for 1 hour at RT. Blocking was then followed by addition of 1 µg/mL HRP-conjugated hTf
(Jackson ImmunoResearch) in 3% BSA in 1x PBS for 1 hour at RT. To show specificity, 1 µL of 1
mg/mL apo-human transferrin [100 µg/mL] was added to with HRP-hTf Comp wells to be used
as a competitor. Wells were washed five times in 200 µL 1x PBS using a BioTek plate washer.
Using the BioTek plate reader, 100 µL of Colorimetric 1-Slow-step TMB ELISA Substrate solution
(Thermo Fisher; catalog# N301; Lot# UG288102) was applied to each well until sufficient color
change was observed after 10-15 minutes. The reaction was quenched with 100 µL 1.8 N H2SO4.
Results were read at 450 nm using a BioTek Plate Reader. Standard curves were completed for
each assay using a range of HRP-hTf between 1 x 10-3 ng and 2 x 10-6 ng. Strains were run in at
least triplicate with standard deviation plotted. The Student t test was used to determine
significance to the positive control FA6905 (p<0.05). Pairwise comparisons with a p value of
<0.05 were considered statistically significant. Values are shown as the means of multiple
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concentration points ± standard error of the mean. Biological replicates were collected in at
least triplicate.
XI. Transferrin binding pulldown with hTf or serum
Gonococcal strains were grown in liquid CDM as described above. Cells were back
diluted after doubling, grown for 3-4 hours, and 1 mL per strain was allocated per well of a 6well dish. Cells were first blocked with 100 µL of 10 mg/mL BSA for 5 minutes at 36°C with 5%
CO2 to prevent non-specific protein binding. Three individual samples of human plasma (LEE
Biosolutions; catalog # 991-58-PS; Lot 01B3177-10) were used for this study. Three donor
samples (Donor # P587039, O+, Female, age 54, Caucasian; Donor# P587070, A+, Male, age 54,
Caucasian; Donor# P587041, B+, Female, age 27, Black and Minority Ethnic) were pooled, filtersterilized with a 0.8 µM filter, and heat-inactivated at 55°C for 15 minutes. After blocking, cells
were incubated with either 8 µL of 125 µM hTf or 20 µL of an estimated 50 µM hTf in human
plasma (191, 200, 331) for 20 minutes at 36°C with 5% CO2. Lysates were standardized and
subjected to SDS-PAGE and western blotting. Images were taken with Bio-Rad ChemiDoc.
XII. Inductively coupled plasma mass spectrometry (ICP-MS)
FA19 WT and mutant strains were grown under iron-stressing conditions in 10 mL liquid
CDM at 36°C with 5% CO2. After doubling, 10 mL of CDM was added to the flasks, and cells were
grown an additional 4 hours. After 4 hours, 800 µL of 125 µM 30% Fe-saturated human
transferrin [5 µM] was added to cells and incubated for 1 hour. After final incubation step, cells
were standardized to 100,000 Ku, and whole-cell lysates were collected as described above.
Remaining cells were pelleted in metal-free tubes at 3570 x g for 5 minutes, washed once in 5
mL of Chelex-treated 10mM HEPES + 1 mM EDTA, pH 7.4 (for 1 L: 2.383 g HEPES and 2 mL of
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0.5M EDTA were added up to volume of 1 L MilliQ water; then treated for 2 hours at RT with 50
g Chelex; followed by filter-sterilization with 0.2 µM filter), and washed twice in 5 mL of 10 mM
HEPES (pH 7.4) (for 1 L: 2.383 g HEPES was added up to 1 L MilliQ water; then treated for 2
hours at RT with 50 g Chelex; followed by filter-sterilization with 0.2 µM filter). Final pellet
masses were recorded for standardization purposes. Pellets were stored at -20°C and sent in
one batch for processing. Digestions and analysis of frozen pellets were performed by
University of Georgia’s Center for Applied Isotope Studies Plasma Chemistry Laboratory.
Statistical analysis was completed in GraphPad Prism 9.0. A Student t test was performed to
determine significance from the positive control, FA19. Pairwise comparisons with a p value of
<0.05 were considered statistically significant. Each strain was tested in at least triplicate. Graph
shows the mean concentration of iron ± standard error of the mean. FA19 and FA6747 were
included in each sample set as controls, and if either showed aberrations to the expected value,
the entire data set was excluded from analysis.
XIII. Homology modeling of TbpA and alignment of the Loop 3 Helix (L3H)
The homology model of TbpA from strain FA19 was generated based on the known
structure of TbpA from N. meningitidis strain K454. Phyre 2.0 was used to generate the PDB file,
and Pymol was used to generate Figure 3.1. ESPript 3.0 was used to generate the multiple
strain alignment and secondary structure prediction of TbpA L3H as previously described (332).
GenBank Numbers include the following: N. gonorrhoeae FA19: EEZ46093.1; N. gonorrhoeae
FA1090: WP_010951283.1; N. gonorrhoeae DG12: EFE04786.1; N. meningitidis K454:
AAF81744.1. The Pymol mutagenesis wizard was used to predict the structural effects from
each mutant (Figure 3.10 and data not shown).
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Chapter 3: The generation and characterization of nonbinding TbpA mutants in the
gonococcus
I. Introduction
Neisseria gonorrhoeae is the causative agent of the human-specific sexually-transmitted
infection, gonorrhea. The World Health Organization (WHO) reported 87 million new cases
globally in 2016 (47), and in 2018 the Centers for Disease Control and Prevention (CDC) has
estimated an approximate 1.6 million new cases occurring in the United States alone (46).
Uncomplicated gonorrhea presents as urethritis in men and cervicitis in women (9, 55, 282,
333). An estimated 80% of gonococcal infections in women are asymptomatic (48, 55).
Asymptomatic cases allow for gonococcal infection to ascend the reproductive track and cause
more severe secondary sequalae, such as pelvic inflammatory disease, ectopic pregnancy, and
infertility (55). Previous gonococcal infection does not provide protective immunity (333-335),
and there has been a rise in antimicrobial resistant strains (47, 336-342). Reports to the WHO in
2018, indicated that 7 out of 65 countries reported isolating gonococcal strains with decreased
susceptibility or resistance to extended-spectrum cephalosporins (336). Drastic increases in
antimicrobial resistance have caused the CDC to modify recommendations for treatment as of
December 2020: uncomplicated gonococcal infection should be treated with a monotherapy of
ceftriaxone (500 mg intramuscular dose (76). Availability of effective therapeutics have
dwindled to the point that researchers are analyzing older antibiotics for alternative treatments
against gonorrhea infection (341). The widespread prevalence of gonococcal infection,
increasing incidence of antibiotic resistance, and lack of protective immunity emphasize the
demand for an effective vaccine.
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Many of the neisserial outer-surface proteins, such as the Opas and pilin, are subject to
high-frequency antigenic variation (90, 301, 343, 344), allowing the gonococcus to effectively
camouflage itself from an adaptive immune response. This genetic adaptability has presented
quite a challenge in vaccine development; however, recently TonB-dependent metal
transporters (TDTs) have been the focus of many vaccine studies (296-303). TDTs are ideal
vaccine candidates because they are highly conserved, present in all pathogenic Neisseria (308),
and most are not subject to high-frequency antigenic variation (283, 301). One such TDT system
in Neisseria acquires iron through the outer-membrane-bound proteins, transferrin-binding
protein A (TbpA) (299, 345). With the help of the lipoprotein TbpB, human transferrin (hTf)
binds to TbpA, and iron is internalized in a TonB-dependent mechanism powered by protonmotive force (308, 345-348). TbpA is required for iron acquisition from hTf (280, 314). While
TbpB increases the efficiency of TonB-dependent iron transport, TbpB is not essential (309,
349). TbpA binds both apo- and saturated transferrin with similar affinity, but TbpB
preferentially binds to 30% Fe-saturated transferrin (312, 313). The importance of the tbpAB
system in gonococcal infection has been demonstrated in a human male colonization study,
where a tbpAB double knockout gonococcal strain was unable to colonize the male urethra
(282).
TbpA and TbpB have previously been evaluated as vaccine candidates for Neisseria spp.
(304, 305, 316). Overall, TbpA demonstrates some protection and immunogenicity but not
enough to be considered a great vaccine candidate (304, 305, 316). Recombinant TbpA (rTbpA)
was first shown to provide protection when used as the sole immunogen to vaccinate mice
against N. meningitidis infection, but no bactericidal activity was observed (304). Consistently,
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follow up studies have shown that TbpB is more immunogenic, eliciting higher bactericidal
activity and serum IgG levels compared to TbpA (304, 305, 316). The immunogenicity of TbpB
has led to increased variability in the amino acid sequence, resulting in less cross-reactive
antibodies compared to anti-TbpA antibodies (305). TbpA is not as immunogenic as TbpB, but
its amino acid sequence is more conserved among strains compared to TbpB (281, 283). TbpA is
also essential for iron acquisition from hTf (280, 314). Overall, TbpB is more immunogenic, but
TbpA is more conserved among Neisseria; therefore, a combination of TbpA and TbpB or other
TDTs is predicted to be more effective than a singular protein vaccine (281, 283, 307).
Tbps have also been targeted as vaccine candidates in several other Gram-negative
pathogens including N. meningitidis (322, 350, 351), Moraxella catarrhalis (352), Actinobacillus
pleuropneumoniae (323), Pasteurella haemolytica (353), and H. parasuis (297, 298, 302, 303,
320, 321). H. parasuis, the etiological agent of Glässer’s disease in pigs, also utilizes TbpA and
TbpB for iron acquisition (297, 298, 302, 318, 319). While there is a current vaccine for Glässer’s
disease, it does not provide the most effective protection (303). A fragment of recombinant
TbpA has been shown to elicit bactericidal activity against H. parasuis (318), but no protection
was observed in challenged pigs (298). TbpB has shown promise as an immunogen in other
pathogens (322, 323), but TbpB failed to provide effective protection against H. parasuis
infection (298, 320, 321). TbpB was still functional and in native conformation and thus, still
capable of binding host transferrin. To examine the immunological effects of host-transferrin
binding to TbpB, a follow up study vaccinated pigs with either wild-type (WT) TbpB or a
nonbinding TbpB mutant (Y167A) and then challenged with H. parasuis (303). Colostrumdeprived pigs were vaccinated with WT or a non-host binding TbpB mutant (Y167A), followed
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by challenge with the porcine pathogen, H. parasuis (303). The TbpB Y167A mutant was
characterized with a 300-fold reduction in binding to porcine transferrin compared to the
native protein (303). H. parasusis challenged pigs demonstrated 100% survival when vaccinated
with the Y167A mutant, whereas, pigs vaccinated with WT TbpB only had 50% survival (303).
Vaccination with both TbpBs was an improvement compared to the currently available Porcilis
Glässer vaccine, which only provided 20% survival (303). Additionally, the TbpB Y167A
vaccinated pigs showed a strong induction of B and T helper 2 responses, suggesting a superior
immune response compared to WT (303).
Factor H binding protein (FHBP) in N. meningitidis has also been evaluated as a vaccine.
Like the TDTs, FHBP binds to a host protein, factor H (fH) in this case. In a transgenic mouse
model, a mutant that was unable to bind to fH produced 4-to-8-fold higher serum bactericidal
antibody responses compared to WT fH (156). Nonbinding TbpB and FHBP vaccination studies
serve as guides for conducting parallel non-host binding TbpA (156, 303). Based on these
seminal studies, we hypothesize that a non-hTf binding TbpA mutant will elicit better
protection and immunogenicity when compared to a WT TbpA antigen in a vaccine study.
The current study aims to expand on previous Tbp structure-function studies by
generating nonbinding TbpA mutants by creating proline mutations in the L3H. Mutant TbpA
gonococcal strains will be characterized for hTf binding, iron uptake from hTf, and growth using
hTf as the sole iron source. The recent generation of a 3 dimensional (3D) crystal structure of
TbpA in N. meningitidis strain K454 has provided essential knowledge to understanding the
mechanism and essential hTf-binding domains (299, 310, 345). Deletion of the L3H prevents the
gonococcus from binding to hTf and internalizing iron from hTf (299, 324). A recent study aimed
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to identify crucial hTf-binding residues in the L3H using point mutations; neutral, alanine, or the
opposite charge mutants failed to demonstrate significantly reduced hTf-TbpA binding (299).
Likewise, these mutants did not show significant reduction in iron internalization from hTf or
disruption in growth when hTf was used as the sole iron source (299). The current study uses
proline-substitution mutations in an effort to generate a TbpA mutant that is unable to bind hTf
with minimal protein conformational changes. An ideal vaccine candidate will retain overall 3D
protein conformation compared to WT and thus, share the same epitopes as WT. Promising
TbpA mutants from this study will be tested for colonization and protection studies in a human
transferrin transgenic mouse model.
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Figure 3.1. TbpA homology model from gonococcal strain FA19 (Adapted from (299))
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Figure 3.1. TbpA homology model from gonococcal strain FA19 (Adapted from (299))
(A) TbpA homology model predicted structure based on the N. meningitidis strain K454 TbpA
crystal structure. The TonB-interacting plug domain is shown in cyan. The L3H is shown in
green. (B) The residues of the L3H targeted for site-directed mutagenesis in this study. (C) A
top-down view of TbpA, demonstrating the plug domain situated in the beta-barrel pore.
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II. Results
A. The TbpA L3H sequence is well conserved at the amino terminal end but residues
are variable at the carboxy-terminal end.
TbpA from N. meningitidis strain K454 has been previously crystalized (308). N.
gonorrhoeae strain FA19 shares 94% sequence identity to the TbpA from N. meningitidis strain
K454 (345). A homology model was generated to demonstrate the predicted structure of
gonococcal strain FA19 TbpA (Figure 3.1). Key components of the TbpA structure include the
outer-membrane embedded beta-barrel motif; key hTf-interacting region, the L3H; and TonBinteracting region, the plug domain (Figure 3.1A and Figure 3.1C). A closer look at the L3H
(Figure 3.1B) shows the key residues that were mutated in this study in order to abrogate hTf
binding. Figure 3.1C shows TbpA from a top-down perspective to demonstrate the location of
the plug domain. Both the FA19 model and the K454 TbpA structure share the L3H, previously
shown to be essential for hTf binding (299, 308, 324). Interestingly, the helical structure is well
conserved at the amino terminal end but contains variable residues at the carboxy-terminal
end, which interacts with the iron ion in hTf during iron acquisition (Figure 3.2). To investigate
the nature of these residues and impact of hTf binding, site-directed mutagenesis was
conducted on several point mutations in the L3H region D355 to Q360, mutating each residue
to a proline (Figure 3.2).
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Figure 3.2. L3H structure and amino acid sequence alignment in Neisseria strains
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Figure 3.2. L3H structure and amino acid sequence alignment in Neisseria strains
(A) An alignment of the TbpA L3H domain amino acid sequences for three N. gonorrhoeae
strains (FA19, FA1090, and DG12) and one N. meningitidis strain (K454). Conserved residues are
highlighted in red. A secondary structure prediction is shown above the residues. Alignment
was generated using EPScript. (B) The FA19 L3H sequence residues that were substituted with
proline for this study (D355-Q360). Conserved residues are written in red, and variable residues
are shown in black.
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B. TbpA is surface exposed in L3H proline mutants.
A previous study characterized several FA19 TbpA L3H point mutants and did not
identify any single residue essential for hTf binding (299). Prior vaccination studies have shown
increased protection when non-host binding mutant proteins are used as an antigen compared
to vaccination with the WT protein (297, 303). Therefore, the main focus of this study is to
identify a non-hTf binding mutant to be used as a vaccine candidate. Our current study
challenges our previous findings by proposing more helix-disruptive proline mutations in leu of
alanine or opposite charge mutations.
To ensure proper expression of TbpA in each mutant, strains were grown in ironstressed conditions and whole-cell lysates were prepared, run on SDS-PAGE, and transferred to
nitrocellulose for western blotting using a polyclonal anti-TbpA antibody (Figure 3.3). The
western blot analysis shows approximately equivalent TbpA protein expression. Because
mutagenesis has the potential to disrupt 3D protein conformation and localization to the outer
membrane, each strain was evaluated for proper surface exposure of TbpA using protease
digestion. Each gonococcal strain was grown in iron-stressed conditions, then subjected to a
time course of trypsin digestion before whole-cell lysates were collected for western blot
analysis (Figure 3.4). As the cells were exposed to trypsin, full length TbpA, approximately 100
kDa, was cleaved into 95 and 55 kDa fragments, as previously described (299, 312). Each
mutant showed a similar pattern to FA19 (WT TbpA). Taken together, this data suggests that
the mutations are not disrupting TbpA expression or surface exposure.
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Figure 3.3. TbpA expression in gonococcal mutant strains
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Figure 3.3. TbpA expression in gonococcal mutant strains
All mutant strains express even levels of TbpA. Whole, iron-stressed gonococcal cells were
standardized, lysed, subjected to SDS-PAGE, and transferred to nitrocellulose membrane.
Western blots were probed with polyclonal TbpA antibody. (A) shows a representative image of
TbpB- mutants. (B) A representative image of TbpA expression in TbpB+ strains. TbpA is 100
kDa. Ponceau S stain was used to confirm equal loading of all wells.
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Figure 3.4. Surface exposure of TbpA proline mutants
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Figure 3.4. Surface exposure of TbpA proline mutants
Whole iron-stressed gonococcal cells were exposed to trypsin for 0, 10, 20, and 30 minutes.
Aprotinin was used to quench the reaction. Lanes “Neg” were not treated with trypsin. Bacteria
were lysed, subjected to SDS-PAGE, and transferred to nitrocellulose membrane. Western blots
were probed with polyclonal TbpA antibody. Full length TbpA is 100 kDa, and trypsin cleavage
of TbpA results in fragments of approximately 95 and 55 kDa.
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C. TbpA L3H proline mutants are deficient in hTf binding.
First, the TbpA mutants were evaluated on ability to bind to 30% saturated hTf. Since
TbpB is capable of binding to hTf, and the presence of TbpB was able to rescue iron uptake
compared to the TbpB deficient strains (299), only tbpB- mutant strains were used for the HRPhTf binding assays. Whole-cell ELISAs of strains lacking tbpB were conducted using HRP
conjugated hTf (Figure 3.5). In these experiments, FA6905 (tbpA+/tbpB-) was used as a positive
control and two negative controls were used: FA6815 (tbpA-/tbpB-) and the FA6905
competitive inhibition (Comp) condition, which included adding 100x excess unlabeled apo-hTf
to HRP-conjugated hTf showing that the HRP-hTf binding is specific to TbpA. A previous study
that identified the L3H as essential for hTf-binding showed that deletion of the L3H resulting in
9% of WT TbpA-binding (299). TbpA point mutations of alanine or the opposite charger reduced
hTf binding to 40-80% of WT levels (299).
The current study found significantly reduced hTf binding in almost every TbpA proline
mutant (Figure 3.5). In mutants with significantly-reduced HRP-hTf binding, binding ranged
from 0.042 to 0.178 pg or 14-58% of WT binding. Two mutants in particular, D355P (0.042 pg or
14% of WT HRP-hTf binding) and A356P (0.055 pg or 18% of WT HRP-hTf binding) showed very
low levels of HRP-hTf binding. Binding levels in the TbpA D355P tbpB- and A356P tbpB- mutants
showed the most significantly decreased hTf binding and were not statistically significant from
the negative controls (Figure 3.5).
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Figure 3.5. TbpA-hTf binding of tbpB- strains
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Figure 3.5. TbpA-hTf binding of tbpB- strains
Whole, iron-stressed gonococcal cells were applied to microtiter dishes for ELISAs using HRPlabeled hTf as ligand. FA6905 (tbpA+/tbpB-) served as the positive control, and FA6815 (tbpA/tbpB-) and the excess competitor apo-hTf condition (Comp) served as negative controls. The
data represent the means ± standard errors of at least three independent experiments. All
strains were compared to the WT FA6905 TbpA positive control. Statistics were calculated with
the Student t test. Significant differences are noted (p<0.05 * p<0.005 ** p<0.0005 ***).
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Figure 3.6. Iron internalization by TbpA proline mutants in (A) tbpB- and (B) tbpB+
background strains
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Figure 3.6. Iron internalization by TbpA proline mutants in (A) tbpB- and (B) tbpB+
background strains
Gonococcal cells were iron-stressed and allowed to bind to 5 µM 30% Fe-saturated hTf for 1
hour. Bacteria were pelleted and washed prior to being subjected to nitric acid digestion for
ICP-MS analysis. Raw µg bacteria/ g iron was plotted for each strain. FA19 (tbpA+/tbpB+) served
as the positive control. FA6747 (tbpA-/tbpB+) served as the negative control. The data
represent the means ± standard errors of at least three independent experiments. All strains
were compared to the positive control. Statistics were calculated with the Student t test. Nonsignificant (ns) was defined as p>0.05. Significant differences are noted (p<0.05 * p<0.005 **
p<0.0005 ***).
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D. TbpA L3H proline mutants are deficient in iron internalization from hTf.
Inductively-coupled plasma mass spectrometry (ICP-MS) was used to measure amounts
of internalized iron and determine if each proline mutation caused a defect in iron
internalization from hTf. The tbpB- strains of the D355P, A356P, N357P, Q358P, and double
K359P Q360P mutants demonstrated significantly lower levels of iron internalization compared
to WT TbpA (FA19) (Figure 3.6). These same mutants in a tbpB+ background did not
demonstrate significant reduction in iron internalization, suggesting that expression of TbpB is
able to compensate for any proline mutations causing reduced iron internalization in a tbpBbackground (Figure 3.6).
E. TbpA proline mutant strains are unable to grow if hTf is the sole source of iron.
Reduction in transferrin binding and internalization does not necessarily suggest that
there will be a reduction in growth when transferrin is used as the sole iron source. Previously,
only the L3H deletion mutant in tbpB+/- backgrounds showed any defect in growth when using
transferrin as a sole iron source (299). Using the same methodology, the growth phenotype of
the TbpA mutants was characterized by plating mutant gonococcal strains onto agar plates
using hTf as the sole source of iron. Approximately equivalent numbers of colonies were struck
out onto Fe-deficient CDM agarose plates supplemented with physiologically-equivalent, 30%
saturated hTf as the sole iron source (Figure 3.7) FA19 (tbpA+/tbpB+) and FA6905 (tbpA+/tbpB)
served as positive controls and FA6747 (tbpA-/tbpB+) and FA6815 (tbpA-/tbpB-) served as
negative controls. Plates were incubated for 48 hours at 36°C and 5% CO2. Both the D355P
mutant and quadruple N357P/Q358P/K359P/Q360P mutant were unable to grow on solid CDM
with hTf as the sole source of iron. As seen previously (299), all tbpB+ strains were able to grow
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like WT (Figure 3.7). Interestingly, the quadruple 357P Q358P K359P Q360P tbpB- mutant was
the only other mutant to show a diminished growth phenotype (Figure 3.7), even though both
the D355P and A356P had the least amount of hTf-binding (Figure 3.5). Interestingly, the D355P
tbpB- and D356P tbpB- mutants both had very significant reduction in hTf binding (Figure 3.5)
and iron internalization (Figure 3.6), but growth phenotypes using hTf as the sole source of iron
were different. The A356P tbpB- mutant was able to grow using hTf as the sole source of iron;
whereas, the D355P tbpB- mutant was unable to grow (Figure 3.7).
To assess the growth defect of the D355P tbpB- mutant further, a similar assay was
performed using liquid CDM. Iron-starved cells were transferred to a 96-well plate and
supplemented with 5 µM hTf and 5 µM desferal to chelate free iron. The OD 600 was plotted
over 24 hours. The D355P tbpB- strain showed significantly reduced growth when iron-starved
gonococci were grown in liquid CDM using hTf as the sole iron source (Figure 3.8).
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Figure 3.7. Growth of TbpA L3H proline mutants on hTf plates
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Figure 3.7. Growth of TbpA L3H proline mutants on hTf plates
Strains were grown on solid CDM agarose plates supplemented with 30% Fe-saturated hTf as
the sole source of iron. CDM agar plates containing 2.5 µM 30% saturated hTf and growth
phenotype for (A) TbpB- and (B) TbpB+ mutants. Approximately equivalent amounts of bacteria
were streaked onto each plate. (A) FA6905 (tbpA+/tbpB-) served as the positive control for
tbpB- mutants, and FA6815 (tbpA-/tbpB-) was the negative control for tbpB- mutants. (B) FA19
(tbpA+/tbpB+) was plated as positive control for tbpB+ mutants, and FA6747 (tbpA-/tbpB+) was
the negative control for tbpB+ mutants.
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Figure 3.8. Growth of TbpA L3H mutants with hTf as the sole source of iron in liquid CDM
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Figure 3.8. Growth of TbpA L3H mutants on hTf as the sole source of iron in liquid CDM
Whole, iron-stressed gonococci were grown in liquid CDM supplemented with 5 µM 30%
saturated hTf over 24 hours. FA6905 (tbpA+/tbpB-) was used as a positive control and FA6815
(tbpA-/tbpB-) served as a negative control. A two-way ANOVA was used to determine
significance in comparison to the positive control. Significant differences are noted (p<0.0005
***).
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F. The TbpA D355P mutant demonstrates reduced serum hTf binding.
To assess if the binding deficiency in the TbpA D355P mutant could be replicated in a
more biologically relevant source of hTf, three samples of human plasma were pooled and used
as a source of hTf to assess hTf binding to TbpA. WT FA6905 (tbpA+/tbpB-) served as a positive
control for hTf binding, and FA6815 (tbpA-/tbpB-) served as a negative control for hTf binding.
The controls and the D355P tbpB- strain were grown in Fe-deplete liquid CDM culture. Cells
were grown 3-4 hours after their first doubling and supplementation with fresh Fe-deplete
media. Cell cultures were first blocked by adding 10 mg/mL BSA in 1x PBS directly to culture to
prevent non-specific protein binding, then either 1 µM hTf or human serum (with
approximately 1 µM of hTf) was allowed to bind for 20 minutes at 36°C 5% CO2. Lysates were
immediately collected, and TbpA and transferrin levels were assayed by western blot (Figure
3.9). Approximately equivalent levels of TbpA were seen in all strains expressing TbpA
compared to WT, but there was reduced binding in the D355P tbpB- mutant in each condition
(reconstituted hTf or plasma hTf). Serum hTf concentrations are estimated to be approximately
30 µM based on the literature; however, preliminary tests suggested that hTf is higher than 30
µM. Serum hTf binding experiments were conducted under the assumption that hTf
concentration was approximately 50 µM; however, the small amount of background binding in
the FA6815 (tbpA-/tbpB-) strain suggests the concentration of hTf in this sample set of serum is
slightly higher.

87

Figure 3.9. The TbpA D355P mutant shows reduced hTf binding compared to WT TbpA.
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Figure 3.9. The TbpA D355P mutant shows reduced hTf binding compared to WT TbpA.
Iron-stressed gonococcal cells were incubated with 1 µM of hTf or approximately 1 µM hTf from
human plasma for 20 minutes. Lysates were collected and subjected to SDS-PAGE, transferred
to nitrocellulose, and probed with polyclonal anti-TbpA antibody and polyclonal anti-hTf
antibody. FA6905 (tbpA+/tbpB-) was used as a positive control, and FA6815 (tbpA-/tbpB-) was
used as a negative control. Ponceau S stain was used to show even protein loading. TbpA runs
at approximately 100 kDa, and hTf runs at approximately 80 kDa.
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G. TbpA D355P and A356P mutants are not predicted to have 3D conformational
changes.
The Pymol mutagenesis wizard was used to predict any structural changes caused by
proline mutations (Figure 3.10). None of the proline mutations were predicted to cause
structural changes (Figure 3.10 and data not shown). Prediction analysis provides evidence that
the proline mutations do not affect overall 3D protein structure; however, this does not replace
further structural analysis.
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Figure 3.10. TbpA D355P and A356P mutants are not predicted to have 3D
conformational changes.
The WT TbpA structure (A) is comparable to the TbpA D335P mutant conformation (B) and
TbpA 356P mutant conformation (C) using the Pymol mutagenesis wizard. Proline mutations
directed to the L3H (green) are highlighted in blue, as indicated by the arrow.
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Figure 3.10. TbpA D355P and A356P mutants are not predicted to have 3D
conformational changes.
The WT TbpA structure (A) is comparable to the TbpA D335P mutant conformation (B) and
TbpA 356P mutant conformation (C) using the Pymol mutagenesis wizard. Proline mutations
directed to the L3H (green) are highlighted in blue, as indicated by the arrow.
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III. Discussion
The TDTs, TbpA and TbpB, are highly conserved, essential for infection for N.
gonorrhoeae, and are not subject to high-frequency antigenic variation; thus, they have been
scrutinized as potential vaccine candidates (281-284, 296, 299, 316). Immunogenicity of TbpA
has been evaluated, but generation of the immune responses is low (305, 316). The ability of a
vaccine antigen to bind to host proteins is hypothesized to inhibit development of a robust
immune response and may explain the weak immunogenicity of WT TbpA, WT TbpB, and WT
FHBP (281, 283, 299, 308). Creation of nonbinding mutants has already been shown to be a
viable option in creating a superior vaccine candidate using TbpB and FHBP (156, 157, 297,
303).
To date, a nonbinding TbpA mutant has yet to be tested as a vaccine candidate to
prevent neisserial infection. The generation of nonbinding TbpA mutants has been facilitated by
the recently available 3D crystal structure of TbpA from N. meningitidis (K454) bound to hTf
(299, 310). Because the gonococcal strain FA19 amino acid sequence is 94% identical to the
meningococcal K454 strain, important structural inferences can be made to identify crucial
binding domains (299). Previously, the L3H was found to be essential for hTf binding to
gonococcal TbpA: when the L3H is deleted, hTf binding is completely abrogated (299). The same
study attempted to identify crucial residues involved in hTf binding, but point mutations to
alanine or the opposite charge did not abrogate hTf-TbpA binding (299). With this is mind, this
current study aimed to target the same L3H of TbpA but insert proline mutations in attempt to
destroy the helical structure (354, 355). Each mutation was generated in strains with and

93

without TbpB to evaluate the impact of TbpB on hTf binding, iron internalization, and growth
when hTf is used as the sole source of iron.
The purpose of our study is to identify a nonbinding TbpA mutant; therefore, the ironinternalization assay results were primarily used to characterize the mutations and provide
more information on a potential mechanism for hTf binding and iron internalization. Our
findings suggest that hTf binding does not necessarily correlate with iron internalization or
growth phenotype when hTf is used as the sole iron source (Figure 3.5- Figure 3.7).
The Q358P tbpB- mutant did not have significantly reduced hTf binding (Figure 3.5) but
showed significant reduction in iron internalization (Figure 3.6). This data suggests that a Q358P
tbpB- mutation may inhibit internalization more than hTf binding but not enough to prevent
growth using hTf as the sole iron source (Figure 3.7). In regards to the double K359P Q360P
tbpB- mutant, iron internalization levels (Figure 3.6) were significantly reduced and comparable
to the D355P tbpB- and A356P tbpB- mutants; however, the double K359P Q360P tbpB- mutant
appears to be more capable of binding hTf (Figure 3.5). The double K359P Q360P tbpBmutation inhibits hTf binding and iron internalization, yet this mutant was still able to grow on
hTf plates (Figure 3.7).
The mechanism of iron extraction from hTf is still being elucidated; thus, further
mutagenesis and structural studies will be key to understanding this mechanism. Ironinternalization data on the L3H TbpA mutants can help us understand the mechanism of iron
extraction from hTf; however, the primary focus of our study was to identify a TbpA mutant
with significantly reduced binding to hTf for use in a gonococcal vaccine. Each proline mutation
at each residue location may cause dissimilar structural changes, and the results of each
94

mutation are difficult to predict. Initially, we hypothesized that the K359 and Q360 residues
would be key hTf-interacting and binding partners based on the positive charge at the end of
the L3H and binding results from the previous mutagenesis study (299). However, this current
study showed that other mutations (D355P and A356P) resulted in the most significant
reduction in hTf binding compared to WT (Figure 3.5).
A reduced growth phenotype (Figure 3.7) coupled with the significant reduction in HRPhTf binding (Figure 3.5) and significantly reduced iron internalization (Figure 3.6) suggest that
the D355P tbpB- mutant is unable to properly bind to hTf and internalize iron. Understanding
the mechanism of the D355P tbpB- mutant seems more straightforward than the A356P tbpBmutant. Both the D355P tbpB- and A356P tbpB- mutants revealed similar reduced hTf binding,
and correlative iron-internalization data (Figure 3.5 and Figure 3.6); however, only A356P tbpBwas able to grow on hTf plates (Figure 3.7). The location of the proline mutation in the helix is
likely to be a key factor in hTf binding, but what each mutation does structurally and how this
affects iron internalization from hTf will need to be further evaluated. The structural
comparison between both D355P tbpB- and A356P tbpB- mutants may reveal that D355P tbpBshows the lowest levels of hTf binding because the 3D structure has been altered to inhibit iron
uptake. In this case, the D355P tbpB- mutant would not be the preferred vaccine candidate.
Our findings suggest that the D355P tbpB- or the A356P tbpB- mutants are the best
vaccine candidates because both showed the lowest hTf-binding levels (Figure 3.5); however,
each point mutation may alter overall protein conformation, biochemical properties, hTf
binding, and TonB-dependent iron internalization. Our hTf-binding deficient TbpA mutants
show similar protein expression levels (Figure 3.3) and protease digestion patterns (Figure 3.4),
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which provides a crude evidence that TbpA mutants are being properly folded and presented at
the surface. Preliminary analysis using the Pymol mutagenesis wizard did not predict any
structural changes to any of the TbpA proline mutants (Figure 3.10 and data not shown). In
addition, TbpB has a strong affinity to hTf and has been shown to compensate for defects in hTf
binding in gonococcal mutants except when the L3H is deleted (299, 309). With the exception
of the L3HΔ strain, all TbpB+ strains were capable of growing like WT; thus, TbpB binding to hTf
is sufficient to rescue the growth of any mutant tested in this study (Figure 3.7). The
compensation observed in all TbpB+ mutants suggests that the TbpA proline mutants are still
functional and able to internalize iron from hTf.
Together these data suggest the TbpA proline mutants have no conformational defects;
however, more robust structural and kinetics studies will be necessary in evaluating any
nonbinding protein as a potential vaccine candidate. A nonbinding mutant that shares similar
structure to WT TbpA is predicted to maintain the same epitopes and thus, elicit a crossprotective immune response during natural infection. Characterization of 3D structure and
functional changes is crucial in understanding how each TbpA L3H proline mutation affects hTf
binding and iron internalization and importantly, which mutant is ideal for vaccine studies. A
nonbinding vaccine candidate that resembles the native protein conformation will share more
similar epitopes and is predicted to elicit a more robust immune response, as antibodies are
more likely to cross-react to native and the nonbinding mutants.
Incorporation of TbpB in a vaccine will require mutagenesis or modification to inhibit
binding to the host, as binding has been shown to reduce immunogenicity (297, 303). Because
anti-TbpB antibodies are less cross-reactive and more immunogenic, and anti-TbpA antibodies
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are more cross-reactive and less immunogenic, a combination of the two is predicted to
enhance protection and the immune response (304, 305, 316). Ideally, nonbinding mutant Tbps
would be included in a vaccine cocktail to increase the cross-reactivity and immunogenicity. As
more TDTs are characterized, nonbinding mutants can be included in this vaccine cocktail to
enhance protection and immunogenicity.
This is the first study to identify a nonbinding TbpA mutant using a single point
mutation. Of interest, the TbpA D355P tbpB- and A356P tbpB- point mutations will be
important to evaluate as potential vaccine candidates. Both have significantly reduced hTfbinding; however, the phenotypic differences in growth on hTf plates suggest that these
mutations have different functionalities and potentially different effects on 3D protein
conformation. Comparison of the 3D protein conformation is expected to be challenging due to
the flexibility of the extracellular loops in nonbinding mutants; however, structural analysis is a
crucial next step.
Each D355P and A356P TbpA mutant will be tested as vaccine antigens alongside WT
TbpA to compare protection against gonococcal colonization in an hTf transgenic mouse model.
The use of a hTf transgenic mouse is essential because TbpA binding is specific to hTf (325).
Because mouse transferrin does not recognize TbpA or TbpB, this provides an explanation for
the enhanced immunogenicity elicited by both proteins when used as vaccine antigens in
mouse models compared to human secretions (304-306, 316). This nonbinding mutant
characterization study and subsequent structural and vaccination studies will serve as
groundwork for future vaccination studies utilizing nonbinding proteins of other TDTs for
Neisseria and other pathogens.
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Chapter 4: Iron, inflammation, and Neisseria gonorrhoeae
I.

Abstract
Iron is essential for metabolic functions in humans and most bacteria. Nutritional

immunity in humans utilizes iron metalloproteins to sequester iron from pathogens to prevent
infection. Neisseria gonorrhoeae, the causative agent of the sexually-transmitted infection
gonorrhea, is capable of extracting iron directly from these metalloproteins, including
hemoglobin, transferrin, and lactoferrin, using specific outer-membrane transporters. Each
metalloprotein has its own ecological niche, and this review will summarize the function and
expression of each protein at gonococcal infection sites. This review will also discuss how other
potential mechanisms for iron acquisition by modulation of host cytokines and proteins could
be advantageous to colonization, invasion, and transmission of the gonococcus.
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II. Gonorrhea
Neisseria gonorrhoeae is an obligate human pathogen responsible for the sexuallytransmitted disease, gonorrhea (356). Gonococcal infections are on the rise: the World Health
Organization (WHO) estimates an approximate 87 million worldwide cases of gonorrhea in 2016
(47). The Center for Disease Control (CDC) recently released an update stating that there were
an estimated 1.6 million new cases in the United States in 2018 (46). N. gonorrhoeae has
become a priority to monitor as a drastic increase in antimicrobial resistant strains have been
observed (47, 336-342). As recently as December 2020, the CDC discontinued the
recommendation for dual therapy with ceftriaxone and azithromycin and instead recommends
doubling the dose of ceftriaxone for treatment of uncomplicated gonococcal infection (76). No
vaccine is available for gonorrhea, and patients can easily be reinfected with the same strain
because prior immunity does not provide any protective immunity against reinfection (333335).
N. gonorrhoeae initially colonizes mucosal sites such as the genitals, conjunctiva, or
oropharynx; gonococcal infections begin as urethritis in men and cervicitis in women (48, 55,
282, 333, 356). Dissemination to the blood stream or disseminated gonococcal infection (DGI)
occurs in less than 3% of cases (58, 60, 356). Gonococcal infection is notorious for being
asymptomatic, especially in women (9, 49, 55). An estimated 80% of cases in women exhibit no
symptoms, and therefore, do not seek treatment, allowing the infection to ascend the
reproductive tract (48, 55). As the infection ascends, inflammation and tissue damage garner,
causing severe secondary sequalae in men and women (9, 45, 55, 56).
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The widespread epidemiology of gonorrhea coupled with limited treatment options
have caused the research community to focus on alternative therapeutics and most
importantly, a vaccine to prevent infection in the first place (356). Recent research has
investigated TonB-dependent transporters (TDTs) as vaccine targets (266, 296, 297, 299, 302,
303, 305-307, 316, 357-361). Many Gram-negatives specifically recognize host metalloproteins,
such as transferrin (Tf), lactoferrin (Lf), hemoglobin (Hb) using outer-membrane transporters
(231, 243, 266, 345, 348, 362, 363). These host metalloproteins are essential for successful
nutritional immunity, as described below. This review will compile the available information of
host iron metalloproteins on the roles in regulating iron homeostasis, availability in key
gonococcal infection sites, and how the gonococcus obtains iron.
III. Iron and the host
Iron is the most abundant metal ion in humans (260, 261). Metals such as iron are
essential for metabolism in most aerobic organisms (192, 196, 260). The soluble and more
bioavailable ferrous (Fe2+) iron is oxidized to insoluble ferric (Fe3+) iron in the host aerobic
environment (272, 364). In the host metabolism, iron is used as a cofactor to form iron-sulfur
(Fe-S) cluster proteins, heme-binding proteins, and RNA reductases, promoting heme synthesis,
oxygen transport, and DNA synthesis (193, 260, 261). Iron is also important for proliferation of
immune cells such as T-lymphocytes and neutrophils (192, 262). While iron is essential, iron
overload is cytotoxic due to generation of reactive oxygen species (ROS) and oxidative stress
(192, 260). The delicate balance of iron levels is stringently regulated in the human host.
Metalloproteins bind and chelate metals to deplete the environment of free metals. Over
99.9% of mammalian iron is sequestered intracellularly, either via ferritin or heme, and the
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extracellular iron is bound to metalloproteins such as Lf and Tf (191, 207). Metalloproteins play
a key role in iron homeostasis by solubilizing iron, making iron bioavailable, and protecting the
host from damaging ROS. Each host iron-binding protein is described below.
A. Hemoglobin
Hemoglobin (Hb) is a globular protein consisting of α and β-globulin chains (231). Inside
erythrocytes, Hb stores approximately 75% of all the iron in the body, and the remaining 25% is
stored by ferritin in liver, spleen, and bone marrow (192, 193, 231, 244, 365). Hb is the most
abundant protein in blood and erythrocytes, and it sequesters iron in the form of heme inside
erythrocytes to prevent high levels of serum free iron (231, 243, 244). Heme is a heterocyclic
porphyrin ring that binds centrally-coordinated ferrous iron (Fe2+) and acts as the precursor to
Hb (231, 244). Heme is typically bound to hemoproteins, such as Hb, haptoglobin (Hp), and
hemopexin, but heme can also be found in the unbound form (231). Hemoproteins bind heme
strongly at one or two of the free iron-coordination sites, which are located perpendicularly to
the porphyrin ring (231). The most common ligand(s) for coordination of the iron in heme are
imidazole groups on histidine side chains; however, methionine, cysteine, and tyrosine have
also been observed (231, 245). Hb may release heme spontaneously or as a result of bacterial
proteases (231, 246). Erythrocytes naturally spontaneously lyse, releasing up to 3 µM free Hb
into serum in healthy patients (231, 246). In serum, the tetrameric Hb dissociates into dimers,
which are rapidly sequestered by Hp (231). Almost irreversibly, Hp binds Hb, and the Hb-Hp
complex is then recycled by macrophages (231, 244, 247). Other serum glycoproteins, such as
albumin and hemopexin, act to rapidly bind and sequester any free serum heme (231).
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i. Plasma
Hb is specific to the blood (366). Hb presence in mucosal secretions is thought to be
contamination from blood. This fact is unsurprising given that the hpuAb system is typically
phase off in gonococcal isolates, except when isolated from women in the early stages of
menses (259).
B. Transferrin
The 80 kDa glycoprotein Tf is the primary extracellular iron protein (192, 193, 207). Tf is
synthesized by hepatocytes and secreted to the serum where it solubilizes ferric iron,
inactivates iron to prevent toxicity, and delivers iron into cells via transferrin receptors (TFRs)
(194). The structure of Tf contains a C- and N-lobe, in which each lobe can bind a single ferric
iron ion (Fe3+). Tf is naturally found at approximately 30% iron-saturation in serum (193, 194).
Saturation of Tf is primarily determined by the rate of iron release from macrophages, when
erythrocyte recycling occurs at a steady rate (194). While inflammation increases hepcidin
concentrations, serum Tf concentrations decrease during inflammation (367).
i. Plasma
Serum Tf is naturally between 12% and 50% (with 30% considered standard) saturation
of the iron-binding capacity (60 to 75 µM), and serum iron levels are calculated to be between
10 to 30 µM (191, 193, 194, 200).
ii. Tears
Tf is hypothesized to travel to the tears by leaking from blood vessels, as it has been
observed in very low concentrations in tears (206).
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iii. Male genital tract
Tf found in seminal plasma is secreted by Sertoli cells, which secrete proteins
responsible for regulating spermatogenesis (368, 369). Early studies looking at Tf levels in
seminal plasma show a range of 30.3 µg/mL to 163.5 µg/mL Tf (368). One study identified a
correlation between low levels of seminal Tf and infertility: levels in vasectomy patients were
13.4 µg/mL compared to 65.6 µg/mL in pregnancy-proven patients (370).
Hormonal regulation was first observed in rat Sertoli cells. Follicule-stimulating hormone
and testosterone were used to stimulate Tf secretion (371). These results suggest that iron is
important for spermatogenesis. N. gonorrhoeae binds to sperm using the asialoglycoprotein
receptor, allowing for transport to another site of colonization (131). The high levels of Tf found
in seminal plasma could provide for ample Tf levels to allow for colonization. The concentration
of Tf in whole ejaculate was 0.07 ± 0.05 mg/mL (with a range of 0.02-0.19 mg/mL) (372).
Interestingly, Tf levels are highest in the earlier phases of ejaculation; whereas, Lf originates
from the seminal vesicles, or later phases of ejaculation (372).
iv. Female genital tract
Proteolytic analysis shows the presence of Tf in vaginal lavages, but specific
concentrations have not been measured (373).
C. Lactoferrin
Lf is an 82 kDa iron-binding glycoprotein similar in structure and function to Tf (205207). Synthesized by neutrophils and exocrine glands, Lf is primarily located in human milk and
mucosal surfaces (208, 210-216). Lf is antimicrobial and anti-inflammatory (206, 208, 209, 374).
Lf has been previously referred to as multiple names including the following: red milk protein,
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Lf 3, lactotransferrin, and lactosiderophilin (212, 375). Lf shares 60% sequence identity with Tf,
and shares a similar structure (217). Like Tf, Lf contains both a C-lobe and N-lobe, where one
Fe3+ ion binds to highly conserved iron site residues on each lobe (205, 218-220). One notable
difference between Lf and Tf is the ability for Lf to maintain high affinity to iron under low pH:
Tf loses its iron-binding affinity below pH 6.5; whereas, Lf maintains affinity down to pH 3.0,
characteristic of many of its sites of expression (205, 216). When no iron is bound, the N- and Clobes of Lf have an open conformation referred to as apolactoferrin. When iron is bound to Lf,
the N- and C-lobes close to form hololactoferrin (218). Because Lf is present in mucosal surfaces
and functional at lower pH values compared to Tf, it is a crucial defense protein in the female
genital tract (216, 331).
Lf has long been studied to understand its role in infection and inflammation. Earlier
studies indicated it as an iron-binding protein similar to Tf, but more recent studies have
indicated it as a regulator of inflammation in some situations (205, 216, 376, 377). Lf is secreted
by cervical or epithelial cells and found in secondary granules of human neutrophils (204, 378385). Fifteen µg of Lf is released from 106 neutrophils (216, 376). For instance, in Lf knockout
mice, the oxidative burst pathway was impaired after treatment with phorbol myristate-13acetate (PMA), a powerful stimulator of the NADPH oxidase-dependent respirator burst (386);
however, no impairment was observed when the Lf knockout neutrophils were treated with
opsonized bacteria (377).
i. Milk
Lf concentrations are highest in colostrum at 7 mg/mL, initially thought to be exclusive
to milk. Lf has been isolated from human colostrum and milk between 2 and 197 days after
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childbirth (212). Lf concentrations were measured at different stages of milk: colostrum (2-5
days postpartum), transitional milk (6-10 days postpartum), and mature milk (11-60 days). Lf
decreased during the first two weeks after childbirth (212). Hormonal regulation of Lf has also
been observed in human colostrum and mature milk samples (385). Milk samples were taken
on day 1, day 4, and days 57-70 after birth: Lf levels were highest on day 1 at 1650 mg/dl,
followed by a sharp decline to 530 mg/dl on day 4, and leveled off to 266 mg/dl on days 57-70
(385).
ii. Plasma
Lf was originally not thought to be present in blood plasma (372, 387), but studies have
identified its presence at levels at median concentration 176 ng/mL (range 39 and 312 ng/mL)
(384).
iii. Tears
Tear Lf was first identified in 1966 (388). Lf is a large proportion of tear protein, 24-27%
in postemenopausal women (388). A study observed a correlation between Lf and epidermal
growth factor (EGF) in middle-aged women with Sjögren syndrome, an autoimmune disorder
characterized by decreased lacrimal gland function (389).
iv. Male genital tract
Masson et al. in 1966 first discovered the presence of Lf in human seminal plasma.
Hekman et al. identified Lf in human seminal plasma, as well as on the surface of spermatozoa;
but not in the testis, epididymis extract, or testicular spermatozoa (387). This study suggested
that Lf originates in the seminal vesicles: no Lf was detected in seminal plasma in patients
without seminal vesicles, and Lf was still detectible in azoospermic semen (387). Lf is secreted
105

by seminal vesicles (372, 387). Reduced seminal vesicle secretion caused by high-dose
testosterone injection, decreased Lf concentrations in seminal plasma (390). The surfacecoating Lf on spermatozoa was suggested to also originate from the seminal plasma (387). Lf
coating spermatozoa could provide several advantages. The bacteriostatic quality of lactoferrin
may provide protection against bacterial infection (387). Additionally, coating of the surface of
spermatozoa with non-specific protein, such as Lf, could allow for less production of antibodies
against spermatozoa or blocking against sperm-specific antibodies in the female genital tract
(387). Buckett et al. compared Lf concentrations among 368 men with varying levels of sperm
density, motility, oligoasthenospermia, or azoospermia. There was no significant difference in Lf
concentration among the groups, ranging from 11.2 mg/100 mL to 13.4 mg/100 mL (391).
Seminal plasma Lf ranges from 0.23 to 2.75 mg/mL with a mean concentration of 1.18± 0.74
mg/mL (372).
Evidence of hormonal regulation of Lf secretion has been observed. Yu and Chen
demonstrated that 17β-estradiol could stimulate mouse epididymis Lf mRNA (392). Elevated
testicular estradiol has been observed during oligospermia (393, 394).
v. Female genital tract
Hormonal regulation of Lf has been observed in the human vaginal secretions (215, 216,
395). The lowest levels of Lf, 3.8 to 11.4 µg/mg, were observed before menstruation, and the
concentrations peaked to 62.9 to 218.0 µg/mg after menstruation (215). Hormonal regulation
was not observed in women taking oral contraceptives, where the mean concentration was less
than 19.8 µg/mg throughout the menstrual cycle (215). Serum Lf levels were also unchanged
throughout the hormonal changes (215). Lf is not considered to be under hormonal regulation
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by oral contraceptives and the menstrual cycle. While the source of the extra Lf during menses
is unknown, it was hypothesized that Lf could leak from the serum into the vaginal mucus;
however, this was not observed in women taking oral contraceptives (215).
vi. Rectum
Fecal Lf is currently being frequently evaluated as a potential biomarker for patients
with inflammatory bowel disease (IBD) (396-399). Fecal Lf levels have mostly been
characterized in patients with IBD, and not much information is available in healthy patients.
Median Lf concentrations in IBD range from 5.7 µg/g to 26.2 µg/g (400).
D. Siderophores
Most Gram-negative bacteria produce siderophores, small molecular weight cages (<1
kDa), that are synthesized and secreted into the environment to scavenge for iron (263-265,
331). Siderophores are a key component that bacteria deploy to combat nutritional immunity.
Siderophores have such a high affinity and specificity to iron that they can pirate iron directly
from Tf, Lf, but not heme (191). N. gonorrhoeae is unable to synthesize siderophores; however,
the gonococcus can use xenosiderophores, siderophores produced by other bacteria, such as
salmochelin and enterobactin (268, 270).
E. Lipocalin
Siderocalins are in the lipocalin family of binding proteins that chelate and inhibit
bacterial siderophores (191, 272, 401). Lipocalin 2 (Lcn2) is a small, 25 kDa protein (402) that
binds to the siderophore enterobactin to scavenge iron in an attempt to inhibit iron piracy by
pathogens (403, 404). The nomenclature of Lcn2 varies throughout the literature. Recent
literature still refers to human Lcn2 as neutrophil gelatinase-associated lipocalin (NGAL), human
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neutrophil lipocalin (HNL), 24p3, uterocalin, and siderocalin (275, 405). This review will focus on
human Lcn2. Lcn2 was first discovered as a neutrophil granule component (402).
Lcn2 primarily and tightly binds bacterial catecholate ferric siderophores but can also
sequester some carboxylates (275). The structure of Lcn2 consists of the standard lipocalin fold
and eight-stranded β-barrel, but the binding pocket of Lcn2 is much larger and consists of more
polar and positively-charged resides compared to other lipocalins (402).
Lcn2 is produced by neutrophils and macrophages; therefore, it is present at mucosal
sites at the initial stages of gonococcal infection and colonization (404). Other cells secrete
Lcn2 including hepatocytes, epithelial cells, and adipocytes (405). Lcn2 has been shown to be
important for regulating iron during infection. Under inflammatory signals, epithelial cells
secrete Lcn2 (402).
i. Plasma
The mean serum Lcn2 concentration for healthy adults was reported to be 63 ng/mL,
ranging between 36 and 106 ng/mL (406), 60.06 ng/mL ± 20.30 (407), and another study
reported lower serum Lcn2 levels in healthy controls (14.30 ng/mL) (408). Another study
reported 30.7 ± 8.1 ng/mL Lcn2 in healthy patients (409). Another study reported significantly
raised serum Lcn2 levels in men (72.1 µg/mL) compared to women (57.6 µg/mL) (410).
Elevated serum Lcn2 levels have been observed in several conditions associated with
high inflammation levels. Lcn2 is upregulated in human papillomavirus (HPV) positive women
compared to HPV negative women (411). Lcn2 concentrations in normal healthy patients were
15,540 pg/mL with a range of 1237-32,872 pg/mL versus HPV positive healthy patients of
39,375 pg/mL with a range of 7778-41,147 pg/mL (411). Patients with IBD demonstrate raised
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systemic Lcn2 levels, possible as a result of high levels of inflammation consistent with IBD (406,
407, 412). Patients with psoriasis, characterized by inflammation, show elevated serum and
tissue Lcn2 levels (409). Evidence suggests that serum Lcn2 and Lcn2-MMP9 (matrix
metalloproteinase 9, with immunomodulatory properties) complex levels are elevated with
obesity, a condition characterized by chronic low-grad inflammation (410, 413). There was no
significant difference in serum Lcn2 (approximately 75 ng/mL) between lean and obese
patients; whereas, Lcn2-MMP9 went from approximately 29 ng/mL to 53 ng/mL (413).
ii. Oropharynx
Bacteria colonization induces expression of nasal Lcn2 in mice (414). There is evidence
suggesting that Lcn2 is proinflammatory and promotes iron sequestration in the mucosa after
addition of enterobactin (414). Lcn2 binds to enterobactin and induces secretion of IL-8, a
neutrophil chemoattractant, in respiratory cells in vitro (414).
iii. Tears
The second most common protein in tears is tear lipocalin, also referred to as lipocalin
1, von Ebner’s gland protein, or human tear albumin (401, 415). First discovered in 1956, tear
lipocalin protects the conjunctiva by scavenging for destructive lipid peroxidation products and
breaking down invading bacterial or viral DNA with catalytic endonuclease activity, and inhibits
microbial proteinases and siderophores to inhibit colonization (401, 415). Lipocalin consists of a
large portion of tear protein. One study measured 1.2 mg of tear lipocalin isolated from 7.2 mg
of total tear protein (415), and another study estimated that 15-33% of tear proteins to be tear
lipocalin (388). Tear lipocalin has several functions, including endonuclease activity. In fact,
lipocalin isolated from tears comprises over 75% of DNA endonuclease activity (415). Tear
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lipocalin is capable of complexing to many tear lipids such as ceramides fatty acids, alcohols,
phospholipids, cholesterol, glycolipids, and diacylglycerols (416).
iv. Female genital tract
Lcn2 levels in vaginal secretions were 456 ng/mL in women with no inflammation, and
Lcn2 levels increased to 780 ng/mL in women with intense inflammation (417). Lcn2 levels
measured in cell-free vaginal lavages are a mean concentration of 1,242 (392-3,432) µg/L (373).
In another study, Lnc2 levels were measured in the vaginal secretions of women diagnosed with
bacterial vaginosis and vulvovaginal candidiasis (418). Lcn2 levels were as follows: control (561
ng/mL), bacterial vaginosis (402 ng/mL), and vulvovaginal candidiasis (741 ng/mL) (418). Murine
lipocalins are not only highly abundant but also demonstrate differential expression throughout
the proestrus, estrus, and metestrus phases (419).
v. Rectum
Lcn2 expression is induced in inflammatory sites of colonic and intestinal epithelial cells
(402, 420-422). Like Lf, Lcn2 has been proposed to be used as diagnostic biomarker for IBD
(397, 422, 423). Inflammation or the diagnosis of such inflammatory bowel diseases, leads to an
increase in Lcn2 expression in the gut. In the mouse, restriction of dietary iron intake reduced
fecal and serum Lcn2, and inflammatory responses induced by bacteria in the gut (424).
IV. Importance of iron acquisition for Neisseria gonorrhoeae
A. Nutritional immunity
Metalloproteins not only protect the host from iron toxicity, but they also play an
essential role in nutritional immunity (192). Nutritional immunity is a host defense against
infection, where metalloproteins sequester valuable nutrients away from pathogens (196, 207).
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Pathogens require metals for essential metabolism and infection, as such, there is a constant
battle between host and pathogen to acquire essential metals. Free (unbound) serum iron
levels range from 10-18 M and 10-24M, which are insufficient levels to allow for bacterial growth:
each bacterial cell requires 105 and 106 M iron (260, 331, 425). Because of the dearth of free
environmental iron, pathogens have adapted ways to acquire metals, such as iron and zinc,
directly from host metalloproteins (260, 331). N. gonorrhoeae acquires iron from several
human host metalloproteins: Tf, Hb, Hp, Lf, and a potential TDT ligand, lipocalin (191).
B. TonB-dependent transporters
TonB-dependent transporters (TDTs) are the main methods for iron acquisition in N.
gonorrhoeae. TDTs are present in most Neisseria strains and are highly conserved, suggesting
that it is essential to survival (266, 281, 283, 296, 311). TDTs are employed by many Gramnegative bacteria to pirate iron, zinc, and other metals directly from host metalloproteins (257,
286, 287, 426). TDTs are characterized as beta-barrels embedded in the outer membrane of
many Gram-negative bacteria (347, 427, 428). A lipoprotein in the outer-membrane often
assists in ligand-binding the beta-barrel receptor (266, 346, 347). In the pore of the beta-barrel
is the plug domain. With the help of TonB, located in the inner membrane, TDTs pirate metals
such as iron and zinc from metalloproteins (286, 287, 299, 345). A metalloprotein, often derived
from the host, serves as the ligand for the receptor. Upon ligand binding, TonB, powered by the
proton-motive force, imports the metal ion into the cell (299, 308).
The mechanism of TDT metal import is still being characterized, but it is hypothesized
that ligand binding creates a conformational change in the receptor, exposing the metal ion to
the plug domain that is located in the pore. After the conformational change, the iron then has
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higher affinity to the plug domain than the ligand; thus, the metal ion then relocates to the plug
domain. TonB is required for release of ligand and pulling the plug domain into the periplasm,
where the metal ion is exposed to a transporter protein that will ferry it to an ABC transporter
in the inner membrane (429). The ABC transporter then imports the metal ion into the
cytoplasm, where it can then be used for essential metabolic processes and ultimately
replication and pathogenesis (308, 345-348).
Several outer-membrane receptors have been identified for iron acquisition, and each
of these transporters have a specific protein that acts as the ligand. To date, receptors have
been described to acquire iron from Tf and Lf, and iron in the form of heme from hemoglobin
(430). TbpA is one of the best characterized TDTs, and hTf serves as the ligand for ironextraction (308). Lactoferrin-binding protein A (LpbA), binds to Lf, and HpuAB binds to Hb and
Hb-Hp complex (226, 231, 243, 362, 431). Several TDTs have been identified to import zinc, but
this review will focus specifically on TDTs and iron (286, 287, 432). TDTs are not constitutively
expressed: pathogens will induce expression of these TDTs exclusively in metal-deplete
conditions to conserve energy (192).
TDTs have been the focus of many vaccine studies (296-303) because they are highly
conserved and present in all pathogenic Neisseria (308). Most TDTs are not subject to highfrequency antigenic variation, which is a mechanism the pathogen employs to evade the
adaptive immune response by having the capability to express exponential versions of everchanging surface antigens (45). For these reasons, the TDTs have been identified as ideal
vaccine candidates (283, 301). This review will summarize the important iron metalloproteins
and tissue localization involved in gonococcal pathogenesis.
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C. The gonococcal hemoglobin receptor system
N. gonorrhoeae acquires iron via heme with the two-component TDT system HbuAB,
where HbuB (85 kDa) functions as the outer-membrane receptor (249, 250), and HpuA (35 kDa)
is a lipoprotein (83, 247, 251, 254). HpuAB binds to Hb, Hb-Hp, and apo-haptoglobin (83). HpuA
and HpuB are both required for acquisition of iron in the form of heme from Hb and Hb-Hp
complexes (83, 251-254). The gene hpuAB undergoes phase variation due to polyguanine (G)
tracts, causing slipped-strand mispairing during DNA replication to cause a functional frameshift
(83, 128, 251).
Another similar receptor system called the HmbR system exists in Neisseria meningitidis;
however, in N. gonorrhoeae, hmbR exists as a nonfunctional, frameshifted pseudogene (257,
258). Gonococcal infection disseminates to the blood stream in less than 3% of cases; thus,
acquisition of iron via heme is likely not as important for the gonococcus than the
meningococcus, which characteristically invades the bloodstream (58, 258). In the female
genital tract, gonococcal isolates taken from women in early menses are more likely to express
HpuAB, suggesting that N. gonorrhoeae is utilizing HpuAB expression when Hb and Hp are
abundant (128, 259). There is evidence that other bacteria extract heme from hemopexin;
however, heme extraction from albumin or hemopexin has yet to be identified in Neisseria
(231).
D. The gonococcal transferrin receptor system
The TDTs, TbpA and TbpB, extract iron directly from host Tf for the gonococcus (266,
299). Gonococcal TbpA is a 105 kDa, 22-stranded β-barrel outer-membrane receptor, and TbpB
is a 75 kDa lipoprotein that facilitates Tf binding to host Tf (266, 299, 433). It has long been
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observed that TbpA is highly conserved and present in all gonococcal strains (225). TbpA
specifically recognizes hTf (434, 435) and is required for Tf utilization (280). TbpB is not
essential for iron acquisition from Tf, but TbpB expression facilitates iron uptake (309). Unlike
its lipoprotein TbpB, TbpA does not have a preference for binding iron-saturated Tf or apo-Tf
(309, 313, 435, 436). In a study of male subjects, a gonococcal strain deficient in TbpA and TbpB
was unable to colonize the male urethra, suggesting that the ability to acquire iron from Tf is
essential for colonization and infection (282).
E. The gonococcal lactoferrin receptor system
N. gonorrhoeae utilize lactoferrin-binding protein A (LbpA) and lactoferrin-binding
protein B (LbpB) to extract iron from Lf (225). Only 50% of gonococcal strains express LbpA;
whereas, all gonococcal strains express the transferrin receptor (TFR) (227, 228, 266, 299). Of
lbpA+ N. gonorrhoeae strains, approximately 30% do not express LbpB, suggesting that LbpB is
not required for the use of the LbpA receptor (225, 229, 230). Additionally, lbpB is subject to
phase variation (311). The lactoferrin receptor supports male urethra gonococcal colonization if
the TFR is nonfunctional (225). Together, these findings suggest that the lactoferrin receptor
provides an advantage for gonococcal colonization but is not essential for gonococcal infection
(225).
V.

Inflammation, iron, and infection
Bacterial infection and inflammation act as signals for the host to deplete iron by

activating an acute phase response and/or upregulating nutrient sequestration mechanisms
(193, 257, 260, 437). Low blood iron was first noted in 1946 during the first 24 hours of acute
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infection in patients (438). Since then, much work has been done to understand the
relationship between inflammation, infection, and iron.
A. Host cellular iron export
The receptor ferroportin and the serum hormone hepcidin regulate iron export into the
plasma (193). Ferroportin is a receptor expressed by iron-storage cells, including hepatocytes
and macrophages, which export iron into serum. Export of iron is tightly-regulated to ensure
that serum iron levels do not reach harmful levels. In iron-repleted conditions, hepcidin binds
to the ferroportin receptor, which triggers degradation of the receptor, and ensues inhibition of
iron efflux (193). The secretion of mediators from erythroid precursors downregulates hepcidin
production as serum iron levels increase (193). In hepcidin-deficient mice, Lcn2 levels are
upregulated, suggesting that Lcn2 may mediate hypoferremia (low serum iron levels) (439).
B. Hepcidin and iron retention in macrophages
Cytokines and tissue damage from inflammation are known to induce hepcidin
production, which promotes iron, heme, and Hb sequestration by macrophages and other ironstorage cells (193, 440). Inflammatory cytokines such as IL-1, IL-6, and IL-22 upregulate hepcidin
production in the liver, which increases intracellular iron stores (441, 442). Synthesis of
hepcidin is stimulated primarily by IL-6 in infection (442). Endoplasmic reticulum stress and
lipopolysaccharide (LPS) have also been found to stimulate hepcidin production (441, 443).
Cytokines also modulate hepcidin production. Tumor necrosis factor alpha (TNF-α) inhibits iron
absorption in the small intestine (444). Pro-inflammatory cytokines such as TNF-α, IL-1, IL-6,
and interferon gamma (INF-γ) modulate iron internalization; however, an increase in iron
storage seems to be situationally dependent (445-448). Anti-inflammatory cytokines such as IL115

4, IL-10, and IL-13 have also been observed to increase iron storage in monocytes and
macrophages (445, 446, 448-451).
C. Recycling of erythrocytes
As serum iron levels dip below 10 to 30 µM, inhibition of erythropoiesis, the synthesis of
erythrocytes, is initiated (193). Maturing erythrocytes require approximately 25 mg of iron daily
to support Hb production, making erythropoiesis the most iron-expensive process in the body
(219, 452). Because dietary iron intake is only an estimated 1 to 2 mg, macrophages have the
important role of recycling iron from senescent erythrocytes to newly produced erythrocytes
(194, 244).
D. The host transferrin receptor
The TFR is expressed ubiquitously in the host and binds to Tf to obtain iron (452). Iron
delivery in erythropoiesis, the synthesis of erythrocytes, is mediated by transferrin receptor 1
(TFR1) (452-455). TFR1 expression is expressed ubiquitously, as all cells require iron, but the
highest expression is found in erythrocytes due to the high need for iron in Hb synthesis (452,
455). Upon hTf binding to TFR1, clathrin-mediated endocytosis imports the hTf-TFR1 complex
into the cell, followed by endosome acidification to release free iron, and recycling of apo-hTf
and TFR1 (452, 456, 457).
TFR2 is ubiquitously expressed, with the highest expression in erythrocytes
(erythroblasts) and hepatocytes, where TFR2 participates in iron homeostasis (452). Recently,
high TFR2 expression has been observed in macrophages, osteoblasts, and neurons (452). The
role of TFR2 in erythropoiesis is still being elucidated, but a role in intracellular iron trafficking
directly to the mitochondria has been suggested (452, 458). TFR2 is primarily associated in the
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lysosome compartment, has a mitochondrial targeting sequence, and associates with MFN2, a
receptor involved in mitochondria-lysosomal contacts (452). Direct iron transfer to the
mitochondria would prevent generation of oxidative stress in the cytoplasm (452). A similar
iron-delivery mechanism has already been observed in neurons (459).
Evidence suggests that TFR1 and TFR2 act as sensors to extracellular iron concentrations
(452). When iron levels drop below the host’s preferred physiological levels, erythrocytes are
used to redirect iron for the most essential processes such as metabolism, host defense, and
neurobehavioral function (193). Iron is stored in hepatocytes and splenic and hepatic
macrophages (193). Macrophages recycle 95% of daily metal needs via erythropoiesis of
senescent erythrocytes (261, 403, 460). In turn, heme is recovered and degraded by heme
oxygenase-1 into iron, biliverdin, and carbon-monoxide (196, 365, 461, 462). Ferritin is highly
upregulated after erythrophagocytosis, suggesting an important role in iron storage in
macrophages (365, 463).
If a pathogen could modulate the TFR, iron internalization could increase or decrease,
depending on the mechanism. Cytokines have been shown to increase iron retention via the
TFR. In human monocytic cell lines THP-1 and U937, cells treated with both INF-γ and LPS
reduced Tf receptor mRNA, protein expression, and iron uptake; however, IL-10 was observed
to stimulate iron acquisition via Tf receptor (445). The same study revealed that combination
treatment of INF-γ and LPS induced expression of divalent metal transporter 1 in a dosedependent fashion, leading to increased uptake of ferrous iron; meanwhile, IFN-γ and LPS
treatment downregulated ferroportin transcription (445). INF-γ downregulates expression of
TFRs as well as intracellular ferritin levels in monocytes (448, 464).
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N. gonorrhoeae can invade cells, including macrophages and neutrophils, which are the
first immune cells to arrive at the site of infection (195). Iron retention in macrophages could be
particularly beneficial for gonococcal infection, as iron retention in macrophages inhibits nitric
oxide formation which normally aids in killing of intracellular bacteria (196). Interestingly, upon
infection of monocytes and macrophages, N. gonorrhoeae can upregulate hepcidin and
downregulate ferroportin, resulting in an overall increase of iron retention (195). N.
gonorrhoeae and Neisseria meningitidis have been shown to reduce expression of the TFR in
infected epithelial cells (465), and N. meningitidis has shown reduction of mRNA levels of host
transferrin receptor 1 (TFR-1) on epithelial cells (466).
VI.

Importance of metalloproteins and N. gonorrhoeae
The role of Lcn2 in gonococcal infection has not been studied. Lcn2 is crucial in

controlling intracellular replication in mycobacteria infection in alveolar macrophages (405).
While Lcn2 is considered protective against bacterial infection, Salmonella is able to exploit
host Lcn2 and calprotectin in the gut (467, 468). No evidence is available on whether N.
gonorrhoeae is capable of exploiting Lcn2, but the role of Lcn2 in gonococcal infection deserves
some investigation. If N. gonorrhoeae is able to bind Lcn2 and extract iron from a bound
siderophore, there may be an unidentified virulence factor, like the TDTs, which could be used
in a vaccine.
If Lcn2 is not exploited by the gonococcus or manipulated to benefit infection, Lcn2 may
be a promising therapeutic. One such method involves utilizing Lcn2 as a scaffold to generate
an anticalin. Anticalins are a novel synthetic alternative to monoclonal antibodies that
recognize specific ligands (469-472). Lcn2 is a small protein (25 kDa), consisting of a simple
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polypeptide chain, and is bioactive without posttranslational modification (469). Lcn2 can be
utilized as a scaffold and modified in order to generate specificity to a specific target (405, 469).
The scaffold structure can be altered to modify plasma half-life, immunogenicity, and tissue
penetrance (405, 469). Anticalins have already been shown to be feasible: digoxigenin-binding
anticalins are specific to digitalis, a cardiac drug, and reversed digitalis toxicity (471). Anticalins
specific to oncofetal fibrinogen (473) and vascular endothelial growth factor receptors (VEGFR)
(474) are currently being evaluated. Development of an anticalin for use in bacterial infection
has been demonstrated as proof of principle in several studies (470). N. gonorrhoeae has
already reached “superbug status,” ushering the development of new treatments and a
vaccine. This review has highlighted several key areas for future therapeutic and vaccine work.
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Chapter 5: Implications, perspectives, and future
The sexually-transmitted infection, gonorrhea, is caused by the Gram-negative pathogen
Neisseria gonorrhoeae (356). Incidence of gonococcal infections is estimated to be 1.6 million
cases in the United States as of 2018 (47). Prior gonococcal infection does not provide
protective immunity, and there is currently no available vaccine to prevent spread of the
disease (333-335). Additionally, antibiotic resistance is on the rise, and N. gonorrhoeae has
been labeled as a key research priority (47, 336-342). Until December 2020, a dual therapeutic
of azithromycin and ceftriaxone was recommended by the CDC for gonorrhea (76). The high
incidence of isolates reported to have resistance to azithromycin has led the CDC to discontinue
the use of azithromycin for uncomplicated gonococcal infection treatment (76). After
discontinuation of azithromycin, the only effective therapeutic remaining is ceftriaxone, of
which resistant isolates have already been reported (76, 342, 475-484). Without effective
treatment, gonococcal infections can ascend the reproductive tract and cause severe secondary
sequelae (9, 45, 55, 56). For these reasons, development of alternative therapeutics and an
effective vaccine is imperative.
TonB-dependent transporters (TDTs) are essential for nutrient acquisition in Gramnegative pathogens (257, 286, 287, 426). TDTs are essential virulence factors for pathogenic
Neisseria. Under metal-deplete conditions, the expression of TDTs is activated, allowing the
pathogen to extract metals such as iron or zinc directly from host metalloproteins (192). The
receptor is located in the outer-membrane of the pathogen, and often a lipoprotein will assist
in ligand binding. Upon binding, the receptor extracts metal from the ligand via TonB,
energetically powered by proton motive force (288, 429). A plug domain resides in the β-barrel
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of the receptor. Upon ligand-binding, activation of TonB pulls the plug domain into the
periplasm. Followed by periplasmic exposure of the metal ion, a metal-binding protein will
transport the metal to an ABC transporter in the inner membrane where the metal will be
internalized to the cytoplasm and used for essential metabolism (Figure 1.3) (266, 345).
Humans require iron for key metabolic processes; however, excess iron generates
reactive oxygen species, which are cytotoxic (192, 260). Excess free iron in the host also
promotes bacterial infections. To thwart bacterial infection, the host employs metalloproteins
to chelate excess free iron (192). N. gonorrhoeae steals iron from host Tf or Lf, and iron in the
form of heme is taken from Hb using TbpA, LpbA, and HpuAB, respectively (Figure 1.2) (226,
231, 243, 362, 431). Tf, Lf, and Hb are found in high abundance at gonococcal infection sites,
including the mucosa and bloodstream. The availability of these aforementioned iron-binding
proteins promotes iron acquisition and subsequent colonization. The gonococcus is also able to
modulate iron regulation in the host by promoting iron retention in several important iron
storage cell types, including macrophages (195) and epithelial cells (465). Iron retention in
macrophages inhibits intracellular killing of bacteria and may allow for increased survival and
ascension of gonococcal infection to the upper reproductive tract (195). Further investigation of
modulation of host iron homeostasis will provide a better understanding of gonococcal
infections and potential ways to hinder infection. Understanding how the gonococcus exploits
host metalloproteins and manipulates host iron homeostasis is relevant for identifying potential
targets for alternative therapeutics, which are highly necessary as the occurrence of antibiotic
resistance increases.
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The siderocalin Lcn2 is also present in high concentrations at key gonococcal infection
sites, which suggests that it may play a role in gonococcal infection. N. gonorrhoeae may
interact or bind Lcn2 for iron acquisition in a similar manner to Tf, Lf, or Hb. Characterizing such
a mechanism could reveal another receptor with vaccine candidate qualities. On the other
hand, if no interaction between N. gonorrhoeae and Lcn2 can be determined, this may suggest
that Lcn2 could be used therapeutically.
The TFR system, including TbpA and TbpB, is perhaps the best characterized TDT (308).
The receptor TbpA, an integral outer membrane protein, binds to hTf, extracts and internalizes
iron for essential metabolic processes (266, 308, 348). The lipoprotein TbpB facilitates
transferrin binding, but is not absolutely required for iron-internalization from Tf (266, 309,
346, 347). TbpA and TbpB are considered ideal vaccine candidates because both are highly
conserved, not subject to high-frequency antigenic variation, and essential to iron-acquisition
from Tf (257, 266, 280-283, 296, 311, 314). Immunogenicity has been characterized for both
proteins in Neisseria (304, 305, 316). Of the two proteins, TbpB is more immunogenic and elicits
more bactericidal activity and serum IgG levels (304, 305, 316). Additionally, the amino acid
sequence of TbpB is more variable than TbpA, and anti-TbpB antibodies are typically less crossreactive than anti-TbpA antibodies (281, 283, 305). In a study using TbpA and TbpB conjugated
to cholera toxin B subunit to intranasally vaccinate mice, anti-TbpB antibodies were less crossreactive but more abundant than anti-TbpA antibodies (305). Vaccination with TbpA and TbpB
epitopes fused to the cholera toxin A2 subunit, elicited bactericidal antibodies specific to TbpA
and TbpB in mice; however, anti-TbpB serum IgG levels were much higher than anti-TbpA (306).
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Sera collected from rabbits vaccinated with intramuscular injection of a rTbpA fragment
elicited polyclonal antibodies specific to rTbpA and demonstrated bactericidal activity against H.
parasuis (318); however, vaccination with rTbpA or rTbpB in colostrum-deprived piglets
provided no protective advantage following challenge with H. parasuis (298). Immunogenicity
of the Tbps has been somewhat inconsistent. Cross-reactive and bactericidal anti-TbpB
meningococcal antibodies have been observed in vaccinated rabbit sera (322) yet, rTbpB
vaccination failed to provide protection from H. parasuis infection in colostrum-derived piglets
(298, 320, 321).
This promising but overall lackluster immune response prompted researchers to
consider methods of improving immunogenicity. Binding to host proteins is hypothesized to
inhibit development of a robust immune response, due in part to the recognition of self-antigen
(281, 283, 299, 308). The ability to bind to host is thought to be a key factor in the poor and
somewhat inconsistent immune response following vaccination with Tbps. The feasibility of
protection using a nonbinding mutant has been shown with TbpB in H. parasuis. Colostrumdeprived pigs were vaccinated with an intramuscular injection of TbpB or a nonbinding TbpB
mutant (Y167A) (303). Pigs vaccinated with the Y167A TbpB mutant yielded better protection
when challenged with H. parasuis and superior B- and T-cell responses in sera compared to pigs
vaccinated with WT TbpB (303). Fifty percent of pigs vaccinated with WT TbpB survived to the
end of the study, whereas, 100% of the pigs vaccinated with the Y167A mutant survived,
suggesting that the nonbinding mutant is a better vaccine antigen than WT (303). Only 20% of
pigs survived after vaccination with the currently available vaccine (Porcilis Glässer), which
implies that vaccination with either TbpB is an improvement (303). This observation of
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improved immunity in nonbinding mutants is not exclusive to the TDTs. The meningococcal
factor H binding protein (FHBP) binds to human compliment factor H (fH), and is already a
component in the Menz4B vaccine. Vaccination with a non-host binding FHBP in a fH transgenic
mouse model elicits higher bactericidal antibody levels than naïve, binding FHBP (156).
This current study aimed to apply the aforementioned concepts to gonococcal TbpA, by
mutagenizing residues of the loop 3 helix (L3H) domain, which is essential for hTf binding (299,
324). The published, cocrystal structure of the meningococcal TbpA (strain K454) bound to hTf
has been instrumental in identifying the L3H as essential for hTf binding (299, 345). Deletion of
the TbpA L3H, prevents the gonococcus from binding hTf, internalizing iron from hTf, and
growing when hTf is used as the sole iron source (299). Our lab previously aimed to abolish hTf
binding by inserting point mutations in the L3H; however, point mutations to alanine or the
opposite charge were insufficient in abolishing hTf binding in gonococcal strains expressing
mutant TbpA (299). TbpA point mutations also failed to show significant impairment of ironinternalization and growth inhibition when hTf is used as the sole iron source (299). Because
alanine or opposite charge mutations were insufficient in generating a nonbinding TbpA
mutant, and because the sequence of the helix is not well-conserved, we hypothesized that the
structure itself was critical for iron extraction. The current study, therefore, proposed to insert
proline mutations on the L3H with the hypothesis being that prolines would be more disruptive
to the helical structure.
The goal of this study was to identify a TbpA mutant with abolished hTf binding. The L3H
of TbpA was mutagenized in gonococcal strain FA19 to characterize the effects of proline
mutations on hTf binding, iron internalization, and growth when hTf is the sole source of iron.
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Single proline mutations were inserted at the following residues: D355, A356, N357, Q358,
K359, Q360. Single point mutations are preferred, because one residue change is less likely to
change the overall protein conformation; however, one residue change may fail to abolish or
significantly impair hTf binding. In the event that one residue change was unable to abrogate
hTf binding, two additional TbpA mutants were analyzed in this study: the double mutant,
K359P/Q360P, and the quadruple mutant, N357P/Q358P/K359P/Q360P. A total of sixteen TbpA
proline mutants were generated: eight L3H mutants were generated in both tbpB+ and tbpBbackgrounds. The TbpA D355P and A356P single point mutations demonstrated the most
significantly reduced hTf binding and are, therefore, the best vaccine candidates.
Vaccination studies will be conducted on both aforementioned mutants to evaluate the
immunogenic response; however, a single-component vaccine is not ideal. A combination
vaccine including nonbinding Tbps and any other TDTs is predicted to elicit a broader immune
response. Multiple proteins provide diverse epitopes and expand the available antibody
repertoire (281, 283, 307). Additionally, the inclusion of TbpA and TbpB in a gonococcal vaccine
would combine the immunogenic and cross-reactive properties of each protein. TbpB is more
immunogenic and variable (281, 305, 306, 316, 485), and TbpA elicits more cross-protective
antibodies (283, 307). Generation of a nonbinding TbpB mutant will require further
mutagenesis studies to abrogate hTf binding, like our study with TbpA.
Because of the variability of TbpB, there is a chance that anti-TbpB antibodies will not
offer great cross-protection. The diversity of TbpB in the Gram-negative pig pathogens
(Actinobacillus pleuropneumoniae, Actinobacillus suis, and H. parasuis) can be broken into 3
groups not based on species specificity (486). The highest sequence diversity in TbpB is
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observed at the transferrin binding face (N-lobe) (486). The phylogenetic tree of TbpA in the pig
pathogens can be broken into more subgroups that primarily follow species divisions, but
sequence diversity is the highest at the hTf-interacting face (486). There is little correlation
between clustering patterns of the TbpA and TbpB phylogenetic trees, suggesting that
horizontal gene exchange occurs independently (486). Phylogenetic analysis of the sequences
of TbpA and TbpB in N. gonorrhoeae and N. meningitidis show the grouping of one subset in
regards to TbpA and two subsets of TbpB (307, 433, 487). The sequence of TbpB is substantially
more variable than the sequence of TbpA, but the hTf-binding interface contains the most
sequence variability in both Tbps (307). Together, sequence analyses suggest that two to three
nonbinding porcine TbpB variants may be feasible and sufficient for cross-protection against
the pig pathogens (307, 357, 486). These results also suggest that two nonbinding TbpB variants
may be necessary for sufficient cross-protection in a neisserial vaccine (307, 433). TbpB of H.
parasuis, a pig pathogen, shares only 24 to 35 % sequence identity to TbpB in TbpB in Neisseria
(data not shown). Because the amino acid sequence of TbpB is so different between Neisseria
and the pig pathogens, extrapolating the use of the Y167A nonbinding mutagenesis studies
cannot be applied to neisserial TbpB. In fact, the H. parasuis Y167 residue is not conserved at all
with Neisseria TbpB. Likewise, the TbpA the amino acid sequence and protein structure are so
different from TbpB that mutagenesis studies cannot be compared between the two proteins.
The highest sequence variability for both Tbps is located at the hTf-interacting region (486). The
L3H of TbpA, which is not shared in TbpB, is located at the hTf-interacting region and essential
to hTf binding (299). This current study targeted the L3H in the hTf-interacting region of TbpA
and identified several mutations that significantly abrogate hTf binding to TbpA.
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The primary goal of this study was to identify a nonbinding TbpA mutant. The available
structural data and initial mutagenesis studies suggested that the last two residues in the L3H,
K359 and Q360, are important for hTf binding, due to their positive charges and vicinity to hTf
(299, 488). Our data suggest that the location of the proline mutation may seem subtle
between two adjacent residues, but even moving the proline mutation one residue provides a
great impact on hTf binding and, presumably, the structure of the helix (Figure 3.1 and Figure
3.2). Further structural analysis will be needed to provide better explanation. The TbpA D355P
and A356P mutants resulted in the most significant reduction hTf binding (Figure 3.5), but
interestingly, only the A356P mutant was able to grow on hTf-loaded plates (Figure 3.7). Both
D355P and A356P tbpB- mutants had significantly reduced hTf binding and iron internalization
levels (Figures 3.5 and Figure 3.6), which implies that both mutants are unable to properly bind
hTf and internalize iron; however, the different growth phenotypes are difficult to interpret
(Figure 3.7). These findings suggest that hTf binding does not necessarily correlate with iron
uptake or growth phenotype on hTf plates. Further structural and mutagenesis studies will
better elucidate the mechanism of iron uptake and relevance of our findings.
This study is the first to abrogate hTf binding by a single point mutation in TbpA. We
recommend that both D355P and A356P mutants be tested as vaccine antigens because hTf
binding was almost completely abrogated (Figure 3.5). Not only will structural and kinetic
studies be essential for identifying the best vaccine candidate, but they may shed light on the
mechanism for hTf binding and iron internalization, which is still not fully understood. Obtaining
a structure for a TbpA that is not complexed to hTf is expected to be difficult because the
extracellular loops are flexible without bound hTf. An ideal nonbinding protein vaccine antigen
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will resemble the 3D conformation of the native protein as close as possible in order to
preserve epitopes and generate antibodies that are cross-reactive to both WT and mutant. How
each D355P and A356P mutation affects the protein conformation of TbpA is not clear;
however, preliminary analysis using western blotting and protease-digestion suggest that each
mutant in this study has a similar conformation to WT TbpA (Figure 3.3 and Figure 3.5).
Additionally, because TbpB has such a strong affinity to hTf, it can compensate for abrogation
of hTf binding to TbpA (Figure 3.5- Figure 3.7), which suggests that the TbpA proline mutants
are functional (299, 309). These data are merely a rudimentary analysis of protein structure;
therefore, both mutants are recommended for further analysis.
Despite similar hTf binding levels, each mutant may elicit a different immune response.
In the previously mentioned TbpB vaccine study in pigs, colostrum-derived piglets were
vaccinated intramuscularly with two mutants (Y167A and W176A) (357). Both mutants targeted
the hTf-interacting N-lobe and share similar biochemical properties and porcine transferrinbinding levels (357). Following challenge with H. parasuis, the Y167A mutant provided
substantial protection, but none of the pigs vaccinated with the W176A mutant survived to the
end of the experiment (357). Immunization with the W176A mutant generated a robust
immune response, produced antibodies, activated B-cells and T-cells, and activated
complement (357). Characterization of the W176A mutant revealed no obvious cause for the
lack of protection (485). These studies emphasize the need for robust characterization of both
D355P and A356P nonbinding mutants and also suggest that the development of protection
using nonbinding mutants is poorly understood.
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A gonococcal vaccine using a nonbinding TbpA mutant has several possible mechanisms
for effectively protecting against gonococcal infections (Figure 5.1). Development of mucosal
IgA antibodies promotes neutralization of gonococci by coating the bacterium with IgA (133).
IgA coating could inhibit the gonococcus from adhering to the mucosa or promote phagocytosis
(133). Development of antibodies could also result in the blocking of hTf binding to TbpA
receptors and subsequent inhibition of iron internalization from hTf. The transferrin receptor
system is required for gonococcal colonization in a male urethral infection model (282),
highlighting the importance of hTf binding in infection. Blocking of Tbp receptors may slow
growth by inhibiting iron uptake; however, the effect on growth and iron internalization will
depend on the levels of antibody and abundance of receptor. As demonstrated previously (299)
and in this study (Figure 3.5 and Figure 3.7), gonococci can grow even when hTf binding is
reduced to approximately 80-90% of WT hTf binding. Anti-Tbp serum antibodies demonstrate
reduced hTf binding and meningococcal growth in mice and rabbit models (489, 490). Vaginal
anti-Tbp antibodies have also been shown to inhibit growth of the gonococcus (306). Blocking
antibodies may facilitate bacterial clearance by slowing gonococcal growth, providing more
time for phagocytosis. Complement-mediated killing is the most important mechanism for
controlling neisserial infection, and studies have shown that anti-Tbp antibodies demonstrate
bactericidal activity in meningococcal (489) and gonococcal infections (305, 306). Lastly, the
generation of opsonic antibodies may promote enhanced gonococcal killing by
opsonophagocytosis, but this has not been evaluated in Tbp vaccination studies to date.
Additionally, Opa-mediated phagocytosis may be affected by anti-Tbp antibodies. Neutrophils
express CEACAMs that effectively bind to gonococcal Opa proteins, resulting in non-opsonic
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phagocytosis and intracellular killing (189). The gonococcus can evade neutrophil-mediated
phagocytosis by recognizing CEACAMs on other tissues to promote adherence and tissue
invasion (189). This evasion strategy is particularly helpful with expression of Opas that do not
recognize neutrophil-specific CEACAMs (189). Anti-Tbp antibodies could coat the pathogen and
make CEACAMs more or less available for Opa-mediated phagocytosis by blocking the Tbp
receptor(s). Antibodies could sterically hinder the interaction between Opas and CEACAMS, or
the blocking of Tbps could facilitate Opa-CEACAM binding. The effect of this mechanism is
dependent on Opa expression. If the gonococcal strain expresses Opas that do not recognize
neutrophils, the gonococcus may gain a selective advantage to adherence and tissue invasion.
On the other hand, neutrophil-specific Opa-CEACAM interactions could promote non-opsonic
phagocytosis and bactericidal killing.
Vaccination studies will be conducted using purified rTbpA as a vaccine antigen in an hTf
transgenic mouse model (Figure 5.2A). Vaccination using hTf mice is the best model to compare
vaccination with WT TbpA and a nonbinding TbpA mutant. Mouse transferrin does not
recognize either Tbp; thus, no comparison can be made between a bound or unbound mutant.
Neither the WT or nonbinding TbpA mutant protein is expected to bind to mouse transferrin;
therefore, WT mice are not a good model for comparing proteins with different hTf-binding
capabilities (325). The ability to express hTf in a mouse will allow us to properly investigate the
true vaccine potential of a nonbinding Tbp mutant.
The inability of mouse transferrin to bind to Tbp antigen is speculated to increase the
immune response. Serum and secretions collected from infected humans did not elicit
antibodies to TbpA or TbpB in serum or secretions (316). Following vaccination with the Tbps,
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antibodies were elicited in mouse serum and vaginal secretions and demonstrated bactericidal
activity and gonococcal growth inhibition (304-306). A similar study used a fH transgenic mouse
model to compare vaccination with WT FHBP or a nonbinding mutant, and the nonbinding
mutant elicited significantly higher bactericidal antibodies compared to WT FHBP (156). We
propose a similar study to compare WT TbpA, D355P, and A356P mutants in a hTf transgenic
mouse model.
Recombinant WT TbpA, D355P, and A356P mutant proteins will be expressed and
purified using E. coli and used for subsequent vaccination studies. First, a colonization study
with determine if either mutant provides superior protection by calculating bacterial clearance,
(Figure 5.2A). Mice will be vaccinated intraperitoneally or intranasally with rTbpA 2-3 times,
followed by challenge with gonococci in either the lower or upper genital tract infection model.
Bacteria will be enumerated from daily vaginal lavages and provide median days of clearance.
The duration of colonization will decrease if protection is observed. If protection is observed,
there are several assays that can be used to characterize the type of immune response in serum
and mucosal secretions: such assays will characterize antibody levels and subclasses,
bactericidal activity, cytokine profiles, opsonization activity, and growth inhibition (Figure 5.2B).
Adjuvants, amounts of antigen, and location of immunization (intraperitoneal or intranasal) are
all known to influence the immune response and will need to be investigated.
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Figure 5.1. Potential vaccine mechanisms

132

Figure 5.1. Potential vaccine mechanisms
Vaccination with a nonbinding TbpA mutant has four potential paths for protection against
gonococcal infection: neutralization, complement, opsonization, and nutritional blocking. Image
made with BioRender.com.
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Figure 5.2. Vaccination model
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Figure 5.2. Vaccination model
(A) shows the vaccination model using hTf mice. Mice will be vaccinated 2-3 times
before being challenged with N. gonorrhoeae to determine if vaccination affects bacterial
clearance rates. (B) If protection is observed, the immunological responses in serum and vaginal
secretions can be characterized based on antibody levels and type, bactericidal activity,
cytokine profiles, growth inhibition, and opsonization. Image made with BioRender.com.
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Delivery of vaccine antigens is an essential step in vaccine research. Production, storage,
and administration contribute to the preservation of the antigens. TbpB production and
purification in E. coli has been established. On the other hand, TbpA is more difficult to produce
as it is much larger and yields fewer amounts of protein due to toxicity to E. coli (307). The
feasibility of mass protein production will need to be considered in development of a TbpA.
Administration of vaccines is challenging. Injecting rTbpA or rTbpB directly into the bloodstream
does not guarantee that proteins antigens are properly folded, which is essential for
development of specific antibodies.
OMVs are a promising avenue for vaccine administration. The Bexsero vaccine provides
proof of principle that OMVs can be an effective vaccine platform. Gram-negative bacteria
naturally release OMVs, spherical bi-layered membrane structures. (491, 492). Production of
OMVs is simple and cost-effective, and the size (diameter 20-50 nm) of OMVs is ideal for cell
uptake (491). The natural bacterial components are intrinsically antigenic, a result of LPS and
other pathogen-associated molecular patterns (PAMPS); however, modifications of the lipid A
structure of LPS can be used to reduce LPS reactogenicity if levels are not tolerable (491). The
membrane component allows for antigens to be displayed in their native conformation, which
is especially a challenge when using a hydrophobic membrane protein, such as TbpA, as a
vaccine. OMVs induce maturation and antigen presentation of antigen-presenting cells (APCs),
which are spatiotemporally-dependent (492).
Our lab has already initiated similar mutagenesis studies on other TDTs, such as TdfH,
TdfJ, and HpuAB. Efforts are being made to create nonbinding mutants similar to this study with
TbpA. Identifying key binding residues is difficult, regardless of the availability of structural
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data. No crystal structure has been resolved for TdfH or TdfJ, and the only available structure
for full-length HpuAB is the Kingella dentrificans homolog, which shares 30% amino acid
sequence identity and 48% similarity with Neisseria (243, 286, 287). Overall, generating
nonbinding mutants has proven to be challenging and difficult to predict, but the combination
of the meningococcal TbpA structure and results of this study can be used as a guide for
selecting key binding residues for mutagenesis targeting other TDTs with similar structures.
Generation of a nonbinding TbpA gonococcal vaccine may also provide protection
against meningococcal infection. Vaccination with the single component MeNZB vaccine has
been associated with reduced rates of gonorrhea after mass vaccination and protection was
estimated to be 31% (493). The meningococcal vaccine, Bexsero, contains the same MenNZB
OMV and three recombinant proteins including NadA, FHBP-GNA2091, and NHBA-GNA1030
(39). Sera immunized with Bexsero elicits antibodies that recognize the gonococcus (39). Most
of the MeNZB-like OMV proteins and NHBA share a high level of amino acid and identify with
the Ngo homologs (44). Gonococcal NHBA produces antibodies that are bactericidal and
opsonophagocytic (44).
The CDC has labeled gonorrhea as a superbug (46, 494). No alternative therapeutic or
vaccine is currently available, and worldwide incidence is at 87 million cases per year (47). The
lack of protective immunity and severity of secondary sequelae in untreated patients
emphasize the urgent need for a vaccine (333-335). The TDTs are highly conserved, not subject
to high-frequency antigenic variation, and have been viewed as promising vaccine antigens
(257, 296). TDTs also play a vital role in metal acquisition for many Gram-negative pathogens.
These studies highlight the importance of iron for the gonococcus and emphasize the
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importance of the source of iron, location in the host, and iron acquisition methods. This study
demonstrates the feasibility in generating nonbinding mutants in TbpA, similar to studies
conducted with TbpB and NHBP (156, 303). This study is the first to identify TbpA mutants that
are significantly defective in hTf binding due to a single point mutation. Ultimately, this study
validates further analysis of nonbinding TbpA mutants for inclusion in a gonococcal vaccine.
These findings can serve as groundwork for future mutagenesis studies in other TDTs, which
can be applied to other Gram-negative pathogens including Neisseria spp., Moraxella spp., and
Haemophilus spp.
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